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Abstract 
Respiratory syncytial virus (RSV) is a ubiquitous human pathogen that produces 
severe lower respiratory disease in vulnerable individuals, characterized by bronchiolitis, 
excessive mucus production, and immune-mediated lung damage. Severe RSV 
bronchiolitis in infancy is strongly correlated with development of recurrent wheezing 
later in childhood, suggesting persistent alteration of the lung immune environment long 
after successful viral clearance. Within the lung environment, dendritic cells (DCs) direct 
innate and adaptive immune responses to viral pathogens through secretion of pro-
inflammatory cytokines and type I interferon (IFN), as well as through activation of 
antiviral T cell responses. Signaling through the RNA-sensing intracellular toll-like 
receptors (TLR) -3 and -7 is required for robust production of type I IFN and antigen 
presentation function by DCs during viral infection. The intracellular process of 
macroautophagy (autophagy), or the sequestration of intracellular contents in a double-
walled membrane for degradation by lysosomes, promotes TLR-dependent innate 
cytokine production and antigen-presenting cell function by RSV-infected DCs. The 
autophagic pathway further limits inflammation by degrading assembled inflammasome 
platforms and their substrate pro-IL-1β, suggesting that autophagy may also block 
excessive pro-inflammatory signaling during infection. However, the requirement for 
autophagy in promoting antiviral responses and limiting lung pathology during in vivo 
RSV infection has yet to be investigated. 
Using a mouse model of lower respiratory tract infection, we found that 
deficiency in the autophagy proteins Beclin-1 (Becn1) or Map1-LC3b (LC3b) led to 
increased lung immunopathology upon infection, characterized by delayed viral 
clearance, increased mucus secretion, and altered T cell cytokine production. Becn1
+/-
 
and LC3b
-/-
 DCs were impaired in antiviral cytokine production, and elicited Th2- or 
Th17- skewed responses from co-cultured CD4+ T cells, respectively. Furthermore, 
studies using bone-marrow chimeric mice revealed a critical role for LC3b in restricting 
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ER stress-dependent, inflammasome-mediated production of IL-1β by infected airway 
epithelial cells. Finally, neutralization of IL-17 or IL-1 receptor signaling in vivo 
ameliorated the development of lung pathology in LC3b
-/-
 mice. Overall, these studies 
shed light on the importance of autophagy to the induction of antiviral immune responses 
and control of inflammation during RSV infection, and establish the autophagy pathway 
as a potential target for future therapeutic interventions. 
. 
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Chapter 1 – Introduction 
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, 
negative-sense RNA virus in the family Paramyxoviridae. It is a ubiquitous pathogen 
which infects the majority of children during their first year of life (1). Since being first 
isolated from a sick chimpanzee in the 1950s (2) and later from infants with pneumonia 
(3), RSV has come to be recognized globally as the most important cause of lower 
respiratory tract infection among infants and young children. Worldwide, approximately 
30 million cases of acute lower respiratory tract infection (LRTI) with RSV occur each 
year in children under the age of 5, with as many as 4 million requiring hospitalization 
(4). RSV is also a significant cause of morbidity among the elderly, immune deficient, 
and immunocompromised (5, 6), as well as for individuals with chronic pulmonary 
disease (7). Despite several decades of research, no safe and effective vaccine is yet 
available, and treatment for patients hospitalized with severe RSV infection largely 
consists of supportive care (8). It is therefore paramount to understand the immunological 
mechanisms underlying the development of severe RSV infections in order to develop 
novel pharmacological treatments for established infections, as well as to ultimately 
inform vaccine development. 
1a. Respiratory Syncytial Virus 
1a.i. Virology and immune evasion by RSV 
The RNA genome of RSV consists of 10 genes,  which encode 11 proteins: Two 
non-structural proteins (NS1 and NS2), nucleoprotein (N), phosphoprotein (P), matrix 
protein (M), small hydrophobic protein (SH), G glycoprotein (G), fusion glycoprotein 
(F), two matrix protein variants from alternate reading frames (M2-1 and M2-2), and 
finally the large RNA polymerase protein (L) (see Figure 1-1). The viral envelope is 
derived from the host cell plasma membrane, and contains the transmembrane G, F, and 
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SH proteins. The M and M2 proteins assemble underneath the envelope, while the L, P, 
and N proteins associate with the single-stranded RNA (see Figure 1-1).  
The G protein harbors heparin-binding domains that facilitate attachment to 
glycosoaminoglycans present on the surface of target cells (9, 10), while the F protein 
binds nucleolin and mediates fusion of the viral envelope and cell plasma membrane, 
releasing the nucleocapsid into the cytoplasm (11, 12). Upon entry, the L protein initiates 
3’ to 5’ transcription of the negative-sense RNA, beginning at a single promoter near the 
3’ end (13–16). As a result, a series of subgenomic mRNAs are produced, and relative 
protein abundance is dictated by proximity to the 3’ end of the viral genomic RNA (14). 
Virion assembly then takes place at the plasma membrane, where the nucleocapsid 
localizes with viral envelope proteins expressed on the host cell membrane. Virions bud 
off of the apical surface of polarized alveolar epithelial cells, where they form clusters of 
long filaments that extend from the cell surface (17). 
RSV infection is typically restricted to the respiratory epithelium and 
intraepithelial immune cells lining the nasal and respiratory tracts (18, 19). Unlike 
influenza virus, RSV induces little cytopathology in in vitro models of polarized 
respiratory epithelium (20–22), at least partially due to its ability to delay programmed 
cell death or apoptosis of host cells. RSV infection induces the upregulation of numerous 
genes encoding inhibitors of apoptosis, including the Bcl-2 family members Bcl-XL and 
myeloid cell leukemia-1 (23–25). Other potential anti-apoptotic mechanisms employed 
by RSV include inhibition of tumor suppressor protein p53 and AKT activation (26) and 
phosphatidylinositol 3-kinase-dependent increases in ceramidase and sphingosine kinases 
(27, 28). Further evidence suggests that the NS-1, NS-2, and SH RSV proteins facilitate 
Figure 1-1 - Human respiratory syncytial virus. Virion structure (A) and ssRNA genome (B). 
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viral replication through suppression of premature apoptosis, resulting in higher viral 
titers (29, 30). 
In addition to inhibiting apoptosis in host epithelial cells, RSV modulates pattern-
recognition receptor (PRR) signaling and resultant cytokine production by the host. 
Epithelial cell surface expression of TLR4 is upregulated within 24 hours of RSV 
infection in vitro, which primes cells for enhanced IL-6 and IL-8 production upon 
exposure to lipopolysaccharide (31, 32). In addition, the RSV F protein interacts with 
TLR4 and CD14 on human monocytes, promoting the production of TNF-α, IL-12, and 
IL-6 (33). Conversely, the NS-1 and NS-2 proteins inhibit production of type I 
interferons by infected host cells through promoting degradation of STAT-2 and through 
binding the cytoplasmic PRR retinoic acid-inducible gene-1 (RIG-I), thereby inhibiting 
activation of the downstream transcription factor interferon response factor 3 (IRF3) (34, 
35).  RSV further inhibits type I interferon production and pro-inflammatory cytokine 
production through antagonism of the TLR adaptor myeloid differentiation factor 88 
(MyD88) (34), as well as through upregulation of suppressor of cytokine synthesis 
(SOCS) gene expression (36).   
The RSV-G protein antagonizes host immune responses through several different 
mechanisms. The protein is produced in both a full-length, membrane-bound version 
(RSV-Gm), as well as in a truncated secreted form (RSV-Gs). As the G protein is an 
important immunological epitope, secreted Gs may serve as a decoy for neutralizing 
antibodies (37). RSV-Gs protein present in the cytoplasm of an infected cell blocks 
TLR3/4-dependent type I interferon production through binding the TLR adaptor protein 
TNF receptor-associated factor (TRAF) (38, 39). The RSV-G protein also bears a 
conserved CX3C motif, suggesting that RSV-Gs is capable of binding the fractalkine 
receptor CX3CR1 and altering the chemotactic activity of leukocytes. Whether this 
serves to recruit leukocytes to the lungs, or to block the effects of endogenous fractalkine, 
is not well understood (40). Finally, the conserved cysteine-rich region of RSV-Gs acts as 
a potent TLR antagonist in vitro, thereby down-regulating TLR-2, TLR-4, and TLR-9-
mediated inflammatory cytokine production (37, 40).   
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Taken together, these varied mechanisms of viral evasion likely contribute to the 
unique epidemiological and immunological characteristics in human patient populations. 
Although RSV has a single serotype with two major antigenic subgroups, the induction of 
immunologic memory to RSV is short-lived, and reinfection throughout life is common 
(1). As no protective vaccine is currently available, it is of vital importance to understand 
the contribution of epidemiologic, immunologic, and environmental risk factors that 
predispose individuals to severe RSV infection. 
1a.ii. Epidemiology of RSV infection 
Respiratory syncytial virus (RSV) is a highly infectious and omnipresent 
pathogen, with up to 70% of infants being exposed within their first year of life (41–46). 
The typical clinical manifestation of disease is a mild upper respiratory infection, with 
20-30% of children experiencing LRTI during the course of infection (47). 
Approximately 1-3% of the annual birth cohort develops LRT bronchiolitis necessitating 
hospitalization, with up to 10% of those hospitalized with RSV-associated bronchiolitis 
requiring admittance to the intensive care unit (41, 42, 45, 48, 49). While numbers vary 
by year, 132-172,000 infants and young children are hospitalized in the United States 
each year with RSV bronchiolitis (50). As many as 200,000 children under the age of 5 
are estimated to die every year from severe RSV infections worldwide, predominantly in 
developing countries (4). 
RSV is unusual in that reinfection is common among young children, with most 
individuals experiencing a decrease in severity of symptoms upon recurrent exposure (41, 
45). While older children and adults have a low incidence of lower respiratory tract 
involvement upon reinfection, individuals who are immunocompromised or elderly are at 
higher risk of developing severe LRTI (5, 6, 51–54). This is especially true among 
individuals with chronic lung conditions such as asthma and chronic obstructive 
pulmonary disease, and is responsible for considerable morbidity among these patient 
populations (7, 55–57).  
The global health burden presented by acute RSV infection is further 
compounded by a strong correlation between infant RSV infection and recurrent 
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wheezing later in childhood. The development of severe RSV bronchiolitis necessitating 
hospitalization is independently predictive of subsequent childhood asthma in multiple 
birth cohort studies (58–68), while others have identified a correlation between clinical 
severity of bronchiolitis and increased asthma risk  (69). Further evidence of a causal 
relationship between RSV bronchiolitis and childhood asthma comes from studies of pre-
term infants receiving prophylactic treatment with Palivizumab, a monoclonal antibody 
to RSV that significantly reduces the severity of RSV bronchiolitis (70). Among multiple 
cohorts of high-risk children, Palivizumab treatment significantly reduced the incidence 
of physician-diagnosed recurrent wheezing (70–74), with other studies finding reduced 
severity of asthma symptoms among treated children (75). Moreover, experimental 
evidence derived from mouse models of virally-induced chronic lung disease point to 
lasting alterations of the lung immune environment consistent with those observed in 
human asthma patients (76, 77). These sequelae of severe RSV infection point to the host 
immune response, and immune-mediated alteration of the lung environment, in 
precipitating subsequent development of chronic lung disease. 
1a.iii. Immune-mediated lung pathology in patients during RSV infection 
One of the most vivid illustrations of the contribution of host immune response to 
the development of severe lung pathology during RSV infection came from early 
attempts at vaccine development. During the 1960’s, infants and children were injected 
with a vaccine containing formalin-inactivated RSV (FI-RSV) in an attempt to elicit 
protective antibody production. In addition to being a poor inducer of neutralizing 
antibodies, the vaccine primed for enhanced disease upon encounter with live RSV. As a 
result, up to 80% of vaccinees were hospitalized upon natural infection, and two children 
died (40). It was initially hypothesized that, given the link between RSV and Th2-
polarized wheezing, the FI-RSV vaccine had induced a Th2-polarized immune response 
upon natural encounter with RSV, leading to infiltration of eosinophils and the over-
production of interleukin (IL)-4, IL-5, IL-13, and possibly IL-10 (78, 79). While some 
experimental evidence supports this concept (80, 81), re-examination of post-mortem 
histological specimens found few eosinophils, and instead reported immune complex 
deposition and neutrophilia in the lungs (79, 82).  
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While the relevance of FI-RSV-induced disease to naturally-occurring RSV 
bronchiolitis is debated, other lines of evidence support over-exuberant immune 
responses as a causal factor of pathogenesis during RSV infection. Clinically, severe 
RSV infection is associated with rapid infiltration of immune cells such as neutrophils 
and monocytes (18, 83), as well as with excessive production of pro-inflammatory 
cytokines (discussed further in the next section). The virus does not appear to be highly 
cytopathic, and infection is generally restricted to the respiratory epithelium and 
intraepithelial lymphocytes (18). In agreement, infants infected with human 
immunodeficiency virus-1 do experience prolonged viral shedding upon RSV infection, 
but do not develop severe bronchiolitis necessitating hospitalization (84).  Administration 
of neutralizing antibodies to RSV to a group of mechanically-ventilated, RSV-infected 
infants successfully reduced viral titers in tracheal aspirates, yet no significant differences 
in disease severity were observed (85). Conversely, the absence of a robust CD8+ 
cytotoxic T lymphocyte response among otherwise healthy infants contributes to 
worsened outcomes and prolonged illness, as the virus is not effectively cleared (19, 86). 
These observations point to a nuanced role for the T cell-mediated antiviral response to 
RSV by facilitating rapid viral clearance, but also exacerbating the development of lung 
pathology in the process. 
1a.iv.Environmental and genetic risk factors associated with severe RSV infection 
The risk of development of severe LRTI in infants is positively correlated with a 
number of factors, including premature birth (<35 weeks gestation), low birth weight, 
congenital heart or lung disease, congenital or acquired immunodeficiency, and inborn 
errors of metabolism (87). Despite the elevated risk conferred by these medical 
conditions, at least half of all infants hospitalized with severe LRTI were previously 
healthy and not considered at increased risk for severe infection (88, 89). Among 
otherwise healthy infants, increased risk of hospitalization is associated with young age 
(<6 months), male sex, older school-aged siblings, and exposure to tobacco smoke (49). 
Conversely, only two protective factors are well-established: Breast-feeding (88, 90, 91), 
and higher circulating levels of maternally-derived neutralizing antibodies to RSV (92, 
93). 
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While no large genome-wide association studies comparing mild and severe cases 
of RSV have yet been conducted, concordance studies between Danish monozygotic and 
dizygotic twin pairs revealed a modest genetic contribution to the risk of hospitalization 
with RSV (94). This is supported by studies examining ethnic background and overall 
risk in infants in the United States, where children of Native Alaskan or American Indian  
heritage are far more likely to require hospitalization in comparison to the general infant 
population (95, 96), while infants of African ancestry experienced less severe 
bronchiolitis than their European-descended counterparts (97). Furthermore, studies of 
the same circulating strain of RSV during the same time period routinely find substantial 
variation in the severity of disease among infected individuals, ranging from mild rhinitis 
to severe LRTI (98).  
Candidate gene studies utilizing 347 known single-nucleotide polymorphisms 
(SNPs) found that risk of hospitalization with RSV is associated with several innate 
immune gene variants, including VDR (vitamin D receptor), IFNA5 (interferon α5), and 
NOS2 (inducible nitric oxide synthase)  (99, 100). Further studies identified an 
association between severe disease risk and SNPs located in other innate immune genes 
such as IFNG (interferon gamma), TGFBR1 (transforming growth factor beta receptor 1), 
and NFKBIA (nuclear factor kappa-B 1A), although the association was only significant 
among preterm children (100). Interestingly, polymorphisms in IL1RN (encoding IL-1 
receptor antagonist) were protective among preterm infants, while increasing risk among 
full-term infants (100). Subsequent examinations of nonsynonymous SNPs present within 
single genes such as lung surfactant proteins  and TLR4 (101–105) found 
overrepresentation of one of two SNP variants among infants with severe LRTI, although 
these findings are not always consistent (99, 106).  
In addition to immunologically important receptor and signaling molecule genes, 
SNPs within the promoter- and coding-regions of critical cytokines are potentially 
associated with risk of severe RSV LRTI. Some studies of cytokine secretion in 
hospitalized infant cohorts found an association between excessive Th2 cytokine 
secretion and disease severity (107, 108), although others have reported little or no 
detection of Th2 cytokines (109–111). Several studies found overrepresentation of 
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common SNPs within the IL-4 gene and promoter regions (112–114), as well as in the 
IL-4 receptor alpha chain (115), among infants hospitalized with severe RSV infections 
in comparison to healthy controls. Polymorphisms within the gene encoding the Th2 
cytokine IL-13 have also been associated with more severe disease, particularly in 
combination with certain IL-4 polymorphisms (113, 116). Numerous studies have also 
examined polymorphisms within the promoter of the Th2-promoting cytokine IL-10. 
Despite some indication that IL-10 promoter polymorphisms alter transcriptional 
regulation of the gene, evidence of higher risk of hospitalization among carriers of these 
SNPs is limited (117–119). One well-known disease-modifying locus on the human 
chromosome 5, labeled 5q31, has been investigated as a potential modifier of RSV LRTI 
severity (113). This locus contains a cluster of cytokine genes, including the Th2 
cytokine genes IL-4, -5, and -13, as well as IFN regulatory factor 1 (IRF1) and 
granulocyte-macrophage colony-stimulating factor (CSF2). The authors identified the 
highest hospitalization odds-risk ratio for infants carrying several SNPs across the IL-4 
and IL-13 genes, especially among infants with no known risk factors (113). However, 
any correlation between haplotype-associated gene polymorphisms and cytokine 
production in response to RSV has yet to be examined. 
As severe RSV LRTI is also associated with excessive influx of immune cells into 
the lungs, SNPs within genes encoding chemotactic cytokines have also been investigated 
for association with severe disease risk. One polymorphism within the promoter region of 
the IL-8 gene, whose product attracts neutrophils, was found to be overrepresented in 
infants hospitalized with severe RSV LRTI (120–122), although subsequent studies did 
not find significant associations with known SNPs within the IL-8 and IL-8 receptor 
genes (123, 124). Additional evidence exists to support increased risk of severe RSV 
among carriers of SNPs within the chemokine CCL5/RANTES (125, 126) and its 
receptor CCR5 (127), which along with CCL3/MIP-1 alpha recruit monocytes, basophils, 
eosinophils, and T cells.  
These studies of genetic and environmental factors contributing to disease 
susceptibility provide interesting correlations with respect to the immune response to 
RSV, yet many findings await rigorous experimental validation. Further studies with 
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large patient populations will be needed to untangle the relationship between genetic, 
epigenetic, and environmental risk factors, and the ultimate development of pathological 
immune responses to RSV. 
1b.Human and murine immune responses to RSV 
In order to protect the host from pathogens, rapid detection of infection by the 
innate immune system is critical. This is accomplished by cells bearing germline-encoded 
pattern-recognition receptors (PRRs), which recognize pathogen-associated molecular 
patterns (PAMPs) present on invading pathogens but absent on host cells. Three different 
classes of PRRs are involved in the detection of RSV: the toll-like receptors (TLRs), 
retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), and the nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) (128). TLRs are type I 
transmembrane proteins expressed on the surface and inside endosomal compartments of 
epithelial cells, dendritic cells, macrophages, eosinophils, and neutrophils. A number of 
TLRs have been implicated in host detection of RSV, including TLR2, TLR3, TLR4, and 
TLR7 (128). The RNA helicases RIG-I and MDA5 are also critical to the detection of 
cytosolic viral RNA (129), while recent studies identify activation of the NLRs NOD2 
and NLRP3 during RSV infection (130, 131). Upon detection of RSV, signaling 
pathways downstream of these PRRs converge at nuclear translocation of the 
transcription factors NFκB and IRF3/IRF7, initiating the production of pro-inflammatory 
cytokines and type I interferons (132). 
The adaptive immune response to RSV is initiated by lung-resident dendritic cells 
(DCs), which are highly specialized in the detection and transport of viral antigens to the 
lung-draining lymph nodes. The instructional cytokines produced by DCs during antigen 
presentation to T cells are critical to the induction of robust, antiviral Th1-polarized 
CD4+ T cells and activated cytotoxic CD8+ T cells. The intracellular processes that 
dictate DC cytokine responses to viral pathogens are therefore capable of eliciting 
protective T cell responses to RSV, or inducing excessive or ineffective T cell responses 
that promote the development of immunopathology. 
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1b.i. Detection of RSV by pattern recognition receptors 
The respiratory epithelium represents a primary interface between the host and 
environmentally-derived antigens and pathogenic organisms, and is the primary target of 
infection for RSV. As RSV infects target cells through fusion with the cell membrane, 
PRRs located in the cytosol of the infected cell are vital to rapid detection of viral RNA. 
The cytosolic RLRs RIG-I and MDA5 bind 5’ triphosphate structures present on single- 
and double-stranded viral RNA using a conserved DExD/H box RNA-binding helicase 
domain, followed by interaction of N-terminal caspase-recruitment domains (CARDs) 
with the CARD domain of the mitochondrial membrane protein IPS-1. This interaction 
induces TBK-1-dependent phosphorylation of IRF3, which then homodimerizes and 
translocates to the nucleus to activate transcription of type I interferons (129). Mice 
deficient in IPS-1 expression (who are therefore unable to signal through RLRs) 
produced very little IFNβ in response to RSV infection, and exhibited worse airway 
neutrophilia and reduced viral clearance (133). RIG-I-dependent signaling is particularly 
critical to NFκB and IRF3 activation during the first hours of RSV infection, enabling the 
rapid production of IFNβ, CXCL10, and CCL5 by infected airway epithelial cells (134). 
RSV infection also induces the upregulation of RLR and intracellular TLR expression in 
vitro, in a manner dependent on IPS-1 expression (135). In agreement, RIG-I and MDA5 
expression were found to be higher in RSV-infected infants in comparison to healthy 
controls (136). Finally, the importance of RLR signaling to enabling the host antiviral 
response is the finding that the RSV NS-1 and NS-2 proteins inhibit RLR signaling by 
blocking interaction of RIG-I with IPS-1 (35). These studies illustrate the importance of 
the RLR/IPS-1 pathway to the early detection of RSV, as well as to the development of 
robust innate immune responses to infection. 
Some evidence exists to support an important role for members of the cytosolic 
NLR family in the detection of RSV and subsequent innate cytokine production. NLRs 
recognize a variety of different PAMPs such as cytosolic bacterial cell products and 
bacterial or viral nucleic acids (137). Recent studies indicate that NOD2 is capable of 
recognizing the single-stranded RNA of several different viruses, including RSV (130). 
Recognition of viral RNA led to a rapid translocation of NOD2 to the surface of 
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mitochondria, and to interaction with IPS-1. This activated both IRF3 and NFκB, leading 
to rapid production of IFNβ (130). Autocrine recognition of IFNβ subsequently leads to 
the upregulation of NOD2 expression, which upon encountering the bacterial antigen 
muramyl dipeptide may amplify pro-inflammatory cytokine production by infected cells. 
The importance of the rapid detection of RSV by NOD2 was further evidenced by 
impaired viral clearance, increased weight loss, and greater lung immunopathology in 
RSV-infected NOD2-deficient mice (130).  
The cytosolic NLR cryoporin/NLRP3 has also recently been shown to recognize 
RSV, and to be required for the production of IL-1β and IL-18 in response to infection 
(131, 138). Direct interaction of RSV-derived PAMPs and NLRP3 has yet to be 
demonstrated, leaving the exact mechanism somewhat unclear. Upon activation, NLRP3 
recruits the adaptor protein ASC to form large multi-protein complexes called 
inflammasomes, which then activates the cysteine protease caspase-1. IL-1β and IL-18 
are translated in an inactive pro-form, which upon cleavage by caspase-1 become 
biologically active (139). In one recent study, mouse bone marrow-derived macrophages 
increased their expression of pro-IL-1β and NLRP3 in response to RSV infection, in a 
process requiring TLR2 and MyD88 (131).  NLRP3/ASC inflammasome complexes 
formed in response to reactive oxygen species and potassium efflux, leading to the 
activation of caspase-1, pro-IL-1β cleavage, and secretion of mature IL-1β (131). These 
findings were recently verified in human bronchial epithelial cells, although the 
production of IL-1β by these cells was dependent on TLR4 expression rather than TLR2 
(138).  
In addition to cytosolic PRRs, airway epithelial cells express membrane-bound 
TLRs implicated in the detection of RSV, including TLR2, TLR3, TLR4, and TLR7 
(128, 140). TLR2 and TLR4 are expressed on the cell surface, where TLR2 forms 
heterodimeric complexes with TLR1, TLR6, CD36, CD14, or dectin-1 to detect PAMPs 
(141). While comparatively little is known about the role of TLR2 in detection of RSV, it 
has been proposed as a potential cellular receptor for RSV, while TLR2/TLR6 signaling 
was shown to activate innate immune responses during RSV infection through promoting 
the production of tumor necrosis factor alpha (TNFα), IL-6, CCL2, and CCL5 (142).  
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In contrast, considerable evidence exists to support the importance of TLR4 
expression to the outcome of the immune response to RSV. The involvement of TLR4 
and CD14 was first identified through demonstration of interaction with the RSV-F 
protein (33), which stimulates NFκB-mediated innate cytokine production (143). Ligation 
of the RSV-F protein by TLR4/CD14 increases TLR4 expression on epithelial cells and 
stimulates production of IL-6 and IL-8 (31, 33, 144). Mice harboring a null mutation in 
the gene encoding TLR4 showed reduced NK cell trafficking and function in response to 
RSV, with decreased IL-12 production and delayed viral clearance in comparison to 
controls (33, 142, 145). Additionally, the expression of two non-synonymous SNPs in the 
ectodomain of TLR4, encoding Asp299Gly and Thr399Ile, has been epidemiologically 
correlated with increased risk of severe RSV bronchiolitis, especially among high-risk 
infants (102–104). Experiments using human bronchial epithelial cells expressing one of 
the two SNPs found reduced translocation efficiency of the receptor to the surface of the 
cell, resulting in decreased NFκB activation and lower production of IL-8, IL-10, IL-
12p35, IL-18, TNFα, CCL8, and type I IFNs in response to stimulation (146). 
Conversely, the expression of TLR4 on blood monocytes was positively correlated with 
disease severity in one clinical study, suggesting potential involvement in the 
development of subsequent lung pathology (147). 
TLR3 and TLR7 are expressed within intracellular compartments such as 
endosomes, where they detect double-stranded or single-stranded viral RNA, respectively 
(141). Upon ligation of the double-stranded RNA intermediate created during the RSV 
replication cycle, TLR3 recruits the adaptor protein TRIF, which activates both NFκB 
and IRF-3 leading to the production of IFNβ and the chemokines CCL5, CCL12, and 
CXCL10 (134, 148, 149). The expression of TLR3 does not seem to be required for 
clearance of RSV in mouse models of RSV infection (150), yet it plays an important role 
in modulating the immune environment and the ensuing development of 
immunopathology.  Ligation of TLR3 promotes the expression of CXCL10 and CCL5 in 
RSV-infected cells, while RSV infection upregulates TLR3 expression in human lung 
fibroblasts and epithelial cells (148, 149). TLR3 expression is also critical to the 
development of a Th1-type antiviral response in vivo, as mice deficient in TLR3 produce 
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greater amounts of the Th2 cytokines IL-5 and IL-13, with more mucus production and 
infiltration of eosinophils into the airways (150).  
TLR7 and its adaptor protein MyD88 are also required for host responses to RSV 
that minimize pulmonary immunopathology. In a manner similar to TLR3-deficient mice, 
TLR7-deficient mice develop altered T-cell cytokine responses characterized by 
increased production of IL-4, IL-13, and IL-17 in response to RSV infection (151). As 
both IL-13 and IL-17 promote airway mucus production (151, 152), RSV-infected TLR7-
deficient mice produced significantly higher amounts of mucus in comparison to wild-
type controls (151). Interestingly, DCs derived from TLR7-deficient mice preferentially 
produce the Th17-promoting cytokine IL-23 at the expense of the Th1-promoting 
cytokine IL-12, potentially contributing to an elevated Th17 response upon RSV 
infection (151).  
1b.ii.Innate cytokine production and immune cell recruitment in response to RSV 
A wide variety of cytokines and chemokines are produced by airway epithelial 
cells in response to RSV infection in vitro, including KC/CXCL1, MIG/CXCL9, IP-
10/CXCL10, fractalkine/CX3CL1, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, 
RANTES/CCL5, IL-6, TNFα, IL-1α/β, and IFN-α/β (143, 153–155). In addition, airway-
resident alveolar macrophages are an important source of CCL3, CCL5, TNFα, IL-6 and 
IFNα in mouse models of RSV infection (156, 157). The secretion of innate cytokines 
and chemokines in murine lungs increases early during infection, with bronchoalveolar 
lavage (BAL) concentrations peaking at 24-48 hours post-infection (155). Expression of 
IL-1, IL-6, and TNFα is also elevated in the early stages of infection, which facilitates 
retention of recruited immune cells and also contributes to their activation. The evidence 
regarding the role of TNFα expression in the clearance of RSV is somewhat 
contradictory, as it is required for viral clearance during the early stages of infection but 
may contribute to the development of lung immunopathology in later phases of infection 
(158–160). The concentration of IL-6 in BAL fluid is also correlated with viral load and 
disease severity, suggesting that it may promote lung pathology in later stages of 
infection (161).  
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Acute RSV-induced lung pathology in human and murine histological samples is 
characterized by bronchiolitis, edema of mucosal and submucosal tissues, and luminal 
occlusion (18). The plugs of material found occluding the airways are reported to be 
composed of apoptotic/necrotic epithelial cells, macrophages, fibrins, and mucins (162, 
163). At the peak of inflammation 7 days post-infection, infiltrating 
monocytes/macrophages and lymphocytes congregate in high density in periarteriolar 
spaces, occasionally extending to adjacent peribronchiolar and alveolar spaces (18, 162, 
163).  
In mouse models of RSV infection, the rapid production of chemokines and 
innate cytokines by airway epithelial cells and alveolar macrophages results in an influx 
of immune cells into lung tissue and peribronchial airspaces. Neutrophils are recruited 
into the lungs as early as 24 hours post-infection in mice (161, 164–168), although the 
kinetics and magnitude of this response is dependent on the isolate of RSV and strain of 
mouse used (169). In contrast, eosinophils generally represent a minor but significant 
component of recruited immune cells in response to RSV (170–173), although some 
studies report no differences in lung eosinophil numbers between RSV-infected and 
control animals (174–176). The primary cell types present in the BAL of infected mice 
are usually monocytes and macrophages, although once again the kinetics of recruitment 
varies between studies (164). Natural killer (NK) cells play a critical role in viral 
clearance during the early stages of RSV infection, and appear in the lungs approximately 
48 hours post-infection (165–168). Influx of NK cells peaks around day 3 or 4 post-
infection, and are generally undetectable by day 8 post-infection (166). 
In contrast to mice, neutrophil recruitment is a prominent feature of severe RSV 
infection in humans, as increased numbers are found in respiratory secretions of patients 
hospitalized with RSV (83, 177, 178). In studies of RSV-infected infants requiring 
intubation, 75-85% of cells in BAL fluid are neutrophils, with numbers being highest 
during the first few days of treatment and declining thereafter (83). Histological 
examination of lung tissue taken from patients who succumbed to RSV infection also 
revealed considerable numbers of neutrophils and monocytes (18, 179). However, some 
studies have found lower numbers of recruited neutrophils in the BAL fluid of 
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hospitalized, RSV-infected pre-term infants in comparison to full-term infants (83). 
Eosinophils are usually detectable in low numbers (<1%) in a minority of RSV-infected 
infants, although one study reported a subset of infants with an average of 3% eosinophils 
in BAL fluid (180).  
In mice infected with RSV, CD4+ T cell recruitment begins early and levels out 
around day 4 post-infection, while CD8+ T cell numbers rise sharply around this time 
(157, 164–166). Numbers of both T cell subsets begin to decline around day 9 post-
infection, but remain elevated in lung tissue through 20 days post-infection. This influx 
of T cells coincides with a second peak in the production of many chemokines in the 
lungs, including eotaxin, CCL3, and CCL5 (155, 161, 181). While T cells constitute a 
small fraction of cells in BAL samples from severe RSV patients (>2%), a significant 
increase in CD8+ T cells was observed in some studies in comparison to uninfected 
controls (177, 182). Histological data on the prevalence of CD8+ T cells in the lungs of 
patients with RSV suggest a protective function, as significant numbers were reported in 
the alveolar interstitium of one infant with non-fatal RSV (18), yet a second study of 9 
fatal cases of RSV revealed a near absence of CD4+ and CD8+ T cells (19).  
In both mice and humans, considerable numbers of dendritic cells (DCs) are 
recruited to mucosal sites during RSV infection. An increase of plasmacytoid DCs 
(pDCs) and monocyte-derived, ‘conventional’ DCs (cDCs) occurs in the lungs and lung-
draining lymph nodes of mice infected with RSV (183–186). Similarly, an influx of cDCs 
and pDCs was noted in nasal washes from infants who were infected with RSV, along 
with decreases in numbers of these cells in peripheral blood (187, 188). The 
indispensable role of DCs in presenting antigen to T cells, and directing appropriate 
polarization of the ensuing adaptive immune response, has long been appreciated. 
However, recent studies suggest that DCs may also be responsible for the induction of 
aberrant CD4+ T cell responses to RSV under certain circumstances, implicating DCs in 
the development of lung immunopathology during RSV infection. 
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1b.iii. Induction of innate and adaptive immune responses to RSV by lung dendritic cells 
Dendritic cells (DCs) are innate immune cells that are found throughout mucosal 
tissues, where they promote immune tolerance to innocuous environmental antigens and 
act as sentinels for invading pathogens. While many lung-resident cells such as epithelial 
cells and macrophages express PRRs and are capable of directing innate responses 
through the production of pro-inflammatory cytokines, DCs are uniquely specialized to 
transport pathogen-derived antigens to lung draining lymph nodes in order to activate the 
adaptive arm of the immune system (189). Thus, through the induction of antiviral CD4+ 
and CD8+ T cell responses and through the production of innate cytokines, DCs initiate 
and orchestrate both innate and adaptive immune responses to viral infection. 
Three distinct DC subsets are known to reside in the lungs in the absence of 
inflammation, all of which perform specialized tasks upon detection of viral infection. 
Intraepithelial DCs, which express the E-Cadherin-binding integrin CD103 in mice 
(CD103+ DCs), intercalate with the epithelial cells lining the respiratory tract and project 
cellular extensions into the airway lumen. A second subset expressing the integrin CD11b 
(CD11b+ DCs) resides in the lamina propria of the major airways, immediately 
underneath the basement membrane (190). Both CD103+ DCs and CD11b+ DCs are 
referred to as myeloid or ‘conventional’ DCs (cDCs), and correspond to mDC1 and 
mDC2 subsets in human lungs (190). Plasmacytoid DCs (pDCs) can also be found in the 
conducting airways in steady-state conditions. Finally, during the course of an 
inflammatory response, monocyte-derived cDCs may be present in the lungs as well, 
characterized by surface expression of CD11b. the monocytic marker Ly6C, and the Fc 
epsilon receptor (FcεRI) (190).  
DCs reside in the lungs in a functionally immature state, where they are poised to 
detect PAMPs such as viral nucleic acids and proteins. All subsets of cDC and pDC 
present within the lungs are capable of being infected by RSV in vitro (191, 192), 
resulting in surface upregulation of MHC class I and II and the costimulatory molecules 
CD80, CD83, and CD86 (183, 191, 193–196). Direct infection of at least some DCs is 
required for DC maturation in response to RSV, as UV-inactivated virus failed to 
stimulate DC maturation in several studies conducted in vitro (197, 198). Upon infection, 
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human monocyte-derived CD11b+ DCs produce the pro-inflammatory cytokines IL-1β, 
IL-6, IL-12, TNFα, and IFNγ (192, 194, 195), as well as chemokines such as CCL2, 
CCL3, CCL5, CXCL8, and CXCL10 (194, 195). In addition, murine bone marrow-
derived DCs (BMDCs) produce the type I interferons IFNα and IFNβ in response to 
infection, which contributes to the surface upregulation of costimulatory molecules in 
these cells (199).  
Upon detection of RSV, murine tissue-resident cDCs rapidly mature and 
upregulate expression of CCR7, enabling the transport of viral RNA and protein to lung-
draining lymph nodes for presentation to T cells (200). The kinetics of migration differ 
depending on the subset of cDC, as numbers of CD103+ DCs in the lungs decrease 
rapidly in the first 24 hours post-infection, while an influx of monocyte-derived CD11b+ 
DCs contributes to increased numbers in the lungs by 7 days post-infection (201). In 
addition, some functional specialization has been noted among intraepithelial CD103+ 
DCs and lamina propria/monocytic CD11b+ DCs with respect to PRR expression, 
antigen acquisition, and T cell stimulation in response to viral infection. As CD103+ DCs 
reside in immediate contact with epithelial cells, these DCs are particularly adept at the 
uptake of apoptotic epithelial cells (202–204), aided by selective expression of TLR3, the 
scavenger receptor CD36, and the C-type lectin Clec9A (205–207). CD103+ DCs 
specialize in stimulating CD8+ T cells through cross-presentation of antigens in influenza 
infection models (208, 209), although this has not been exhaustively investigated in RSV. 
In contrast, CD11b+ DCs selectively express TLR2 and TLR7 (203), and are major 
producers of chemokines which attract effector cells to the lungs during pulmonary 
infection (210, 211). CD11b+ DCs are also reported to preferentially activate CD4+ T 
cells in the context of severe influenza infection (212) and studies of directly-infected 
CD11b+ DCs indicate proficiency in priming a CD8+ T cell response (213, 214). Less is 
known about the specialization of these cells in the context of RSV, although ex vivo co-
culture experiments suggest that RSV-infected CD103+ DCs and CD11b+ DCs are 
capable of stimulating both CD8+ and CD4+ T cells (201).  
Despite the ability of DCs to rapidly mature and produce innate cytokines in 
response to RSV infection, RSV appears to reduce the capacity of DCs to stimulate and 
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induce proliferation in naïve T cells (184, 192, 197, 198). Infected DCs release an as-yet 
unidentified soluble factor that suppresses T cell activation in a dose-dependent manner 
(197, 215), which is independent of IL-10, TGFβ, or the activity of regulatory T cells 
(184). This effect may be due to synergistic activity of IFNα and IFNλ (215), or to 
ligation of a combination of receptors to IFNα, IL-10 and IL-28 (215). In addition to 
stimulating the release of a soluble suppressor of proliferation, RSV may interfere with 
immune synapse formation that takes place during presentation of antigen to naïve T 
cells. One study found that naïve T cells fail to polarize their Golgi to the site of synapse 
formation during interactions with RSV-infected DCs, suggesting that inadequate DC-T-
cell interaction may be responsible for observed impairment in T cell stimulation and 
proliferation (198). T cells stimulated with RSV-infected DCs were subsequently 
nonresponsive to proliferation signals such as IL-2 and anti-CD3 antibody treatment 
(197, 198), and were impaired in the production of IL-2, IL-4, IFNγ, and TNFα, all of 
which is suggestive of an anergic state (196, 197, 216).  This phenomenon is only 
observed in DC-T cell co-cultures where the DCs are infected with replication-competent 
virus, as naïve T cells cultured with DCs exposed to UV-irradiated RSV showed no 
proliferation defects (197, 198). Similarly, RSV-infected DCs were able to efficiently 
stimulate proliferation and cytokine production from memory T cells, suggesting that 
RSV only interferes with naïve T cell stimulation (196). This subversion of DC antigen-
presentation to naïve T cells likely contributes to weakened primary responses to RSV in 
human infants, potentially increasing the likelihood of severe LRTI. 
1b.iv. Involvement of lung dendritic cells in protective and pathogenic responses to RSV 
Lung DCs are uniquely positioned to promote protective or pathological immune 
responses to RSV infection through the induction of adaptive T cell responses and 
through production of pro-inflammatory cytokines that influence the immune 
environment of the lungs during infection. In order to develop an effective antiviral 
response to RSV, different DC subsets must work synergistically to facilitate swift viral 
clearance with minimal damage to uninfected tissues. On the other hand, evidence from 
clinical studies and mouse models of RSV suggest an immunopathological role for 
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certain DC subsets, highlighting the complexity of DC-mediated immune responses 
during infection. 
While pDCs are poor presenters of RSV antigens to T cells, evidence suggest that 
they are critical sources of IFNα, pro-inflammatory cytokines, and chemokines upon 
exposure to RSV (183, 185, 217). Human pDCs isolated from peripheral blood also 
secrete innate cytokines and large amounts of IFNα in response to RSV infection, 
implicating these cells as important mediators of antiviral immunity (192, 218). In studies 
of RSV infection in mice, increased numbers of pDCs in the lungs appears to be 
protective, while depletion of pDCs results in increased viral replication, greater mucus 
production, and prolonged airway hyperreactivity in RSV-infected mice (183, 185). As 
numbers of pDCs in the lungs increase by day 3 post-infection and decrease below 
homeostatic levels prior to the onset of peak inflammation, IFNα production by pDCs is 
likely to be the most critical to early antiviral immune responses during RSV infection 
(183–185).  
As cDCs within the lungs are tasked with the induction of CD4+ and CD8+ T 
cell-mediated responses to RSV, the ability of these cells to stimulate strong antiviral 
Th1-type responses is critical to successful viral clearance (189). By presenting antigen to 
naïve and RSV-reactive memory T cells, migratory lung cDCs induce the proliferation 
and differentiation of effector ‘helper’ CD4+ T cells and cytotoxic CD8+ T cells, which 
migrate to the lungs and clear virally-infected cells (190). While the actions of CD4+ and 
CD8+ T cells are critical to viral reduction and the eventual eradication of RSV, these 
cells are also involved in the development of lung immunopathology (219–223). By 
depleting CD4+ or CD8+ T cells during RSV infection in mice, it was found that both 
viral clearance and lung pathology were reduced (219). Similarly, the transfer of RSV-
specific CD4+ and CD8+ T cells to infected mice increased viral clearance, but led to the 
development of increased lung pathology (220, 221). Sustained activity of T cells is also 
linked to increased airway hyperresponsiveness in RSV infected mice (220), further 
supporting the dual role of T cells in viral clearance and pulmonary damage during RSV 
infection. 
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Some evidence suggests that certain DC subsets also contribute to the production 
of Th2-type responses to RSV and lung immunopathology in mice. Studies in both mice 
and human infants note an influx of monocyte-derived DCs into the respiratory tract and 
draining lymph nodes during RSV infection (184, 186–188, 199), which may contribute 
to overall inflammation and hyper-responsiveness to both RSV and subsequent allergen 
challenges (186, 211, 224, 225). Blockade of migration of monocyte-derived CD11b+ 
DCs to the lungs or lung-draining LNs is protective against RSV-induced 
immunopathology in mice, resulting in more robust Th1 responses and enhanced viral 
clearance (226, 227). The relative abundance of these DCs within the lung environment is 
also implicated in the development of pathological responses to RSV in vivo, as the 
addition of monocyte-derived CD11b+ DCs increases Th2 responses and associated lung 
pathology during RSV infection of mice (217, 227, 228).  
Because of the distinctive capacity of DCs to direct both innate and adaptive 
immune responses to pulmonary viral infections, the intracellular mechanisms which 
control DC responses to RSV are of particular interest. Through the transport of viral 
peptides to lung-draining LNs for antigen presentation, and through production of innate 
cytokines, DCs provide critical instructional signals that elicit antiviral Th1 responses by 
RSV-reactive T cells. As DC maturation and production of innate antiviral cytokines are 
dependent on recognition of RSV through TLRs (34, 229, 230), the processes which 
facilitate the transport of viral material to TLR-containing endosomes are of paramount 
interest. Recent studies into the process of macroautophagy, whereby cytosolic contents 
are enveloped in a double-walled membrane and delivered to endosomes, have revealed a 
crucial role for autophagosomes in the antiviral response of DCs. Through expanding the 
ancient homeostatic functions of autophagosome formation and maturation, DCs expedite 
the delivery of intracellular pathogen-derived nucleic acids and peptides to endosomal 
compartments, thereby facilitating the production of appropriate innate cytokines and the 
loading of viral peptides onto MHC-II molecules for presentation to CD4+ T cells. 
1c. Autophagy in immune defense against viruses 
The process of macroautophagy, hereafter referred to as autophagy, is thought to 
have initially evolved as a mechanism to enable survival of unicellular organisms during 
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periods of nutrient scarcity. To this end, autophagosomes envelop cytosolic organelles or 
proteins in a double-walled membrane, enabling the degradation of the contents upon 
fusion of the autophagosome with lysosomes. Macromolecules recovered from degraded 
autophagosomal contents may then be used to prolong cell survival until favorable 
conditions return (231). In addition to facilitating cell survival and enabling the removal 
of unneeded or damaged protein aggregates and organelles, the molecular machinery of 
autophagosome formation has been recruited for cellular defense against cytosolic 
pathogens in metazoan organisms (232). Recent studies have demonstrated additional 
immunological requirements for autophagy in DCs as a mechanism enabling the capture 
and delivery of cytosolic macromolecules to intracellular compartments containing TLRs 
and MHC-I/II peptide loading machinery (232). Conversely, autophagy antagonizes 
production of the pro-inflammatory cytokines IL-1β and IL-18 through selective 
degradation of assembled inflammasome platforms and their substrates pro-IL-1β and 
pro-IL-18 (233). The removal of depolarized mitochondria through mitochondrial 
autophagy (mitophagy) is also critical to the regulation of inflammasome activity within 
innate immune cells, as disrupted mitochondria are an important source of 
inflammasome-activating reactive oxygen species (ROS) (234, 235). Finally, signaling by 
sensors of ER stress, which activate the unfolded protein response (UPR) during 
pathogenic insult, also activate autophagosomal machinery in an attempt to restore 
homeostasis through removal of ER (ER-phagy), damaged mitochondria, and 
accumulated proteins (236). These processes collectively suggest an important 
immunomodulatory role for autophagy during viral infection, in both promoting critical 
antiviral cytokine production and APC function in DCs, as well as in minimizing 
pathological inflammation through the limitation of excessive pro-inflammatory cytokine 
production during infection. 
1c.i. Autophagosome formation and maturation 
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The process of autophagosome formation is highly conserved among eukaryotic 
organisms, and the pathway was first elucidated with studies in yeast ((231), see Figure 
1-2). Autophagy is initiated during starvation by the inhibition of the mammalian target 
of rapamycin (mTOR) and activation of AMP-activated protein kinase (AMPK), which 
phosphorylates ULK1 and cause the translocation of the ULK1 complex to the 
endoplasmic reticulum (ER) (237, 238). While the primary source of membrane in the 
formation of autophagosomes is thought to be the ER, some studies suggest that 
membrane material can also be contributed by mitochondria, the Golgi apparatus, the 
nuclear membrane, or even the plasma membrane (231). The phosphorylated ULK1 
complex activates the VPS34-containing class III phosphatidylinositol-3-OH kinase 
(PI3K) complex located on the ER surface (VPS34-PI3K), which includes the class III 
PI3K VPS34, VPS15, autophagy protein (ATG) 14, and ATG6/Beclin-1 (Beclin-1) (237, 
239). The VPS34-PI3K complex then produces phosphatidylinositol-3-phosphate, which 
recruits DFCP1 and WIFI family proteins that initiate the extension of source membrane 
into pre-autophagosomal structures termed omegasomes (240, 241).  
Figure 1-2 – Autophagosome formation and maturation. A) Autophagy induction is regulated by mTORC1 and 
AMPK in mammals. Phosphorylated ULK-1/2 (homologs of yeast ATG1) activates the VPS34-PI3K complex, which 
contains Beclin-1. Autophagic cargos are indisicriminantly obtained from the cytoplasm, or are targeted to nascent 
autophagosomes through sequesteosome proteins such as p62. Complete autophagosomes dock and fuse with 
lysosomes, leading to the degradation of the contents, as well as the inner autophagosomal membrane. B) Two 
ubiquitin-like conjugation systems, producing (i) PE-conjugated LC3-II, which is incorporated into outer and inner 
autophagosomal membranes. (ii) ATG5/12/16L complexes facilitate membrane elongation and curvature, and 
dissociate from the surface of fully-formed autophagosomes (not pictured). 
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The elongation and closure of the double-walled autophagosomal membrane is 
dependent on two ubiquitin-like conjugation cascades. The first involves creation of the 
ATG5-ATG12 conjugate through actions of the E1-like ATG7 and the E2-like ATG10. 
This conjugate then forms a dimeric complex with ATG16L1 on the outer membrane of 
nascent autophagosomes (242). The second conjugation system, which requires ATG7 
and the E2-like ATG3, cleaves and conjugates ATG8 homologs with 
phosphatidylethanolamine (PE). The PE-conjugated ATG8 homologs, which in mammals 
are LC3, GATE16 and GABARAP, are incorporated into the inner and outer 
autophagosomal membranes (243, 244) (Figure 1-2). Finally, the maturation of the 
completed autophagosome is accomplished by fusion with acidic lysosomal 
compartments containing hydrolases that degrade the autophagosome contents, as well as 
the inner autophagosomal membrane. This occurs through the recruitment of the SNARE 
protein Syntaxin 17 to the outer membrane, which enables docking and fusion with 
lysosomes to form an autolysosome, whose contents are degraded (245). 
The sensing of sudden nutrient scarcity caused by microbial invasion may have 
been the evolutionary basis for the involvement of autophagy in removal of invading 
intracellular pathogens. This is evidenced in modern innate immune cells through the 
integration of immunological and metabolic signaling which triggers autophagy, centered 
on the regulation of Beclin-1 (232). During starvation, the ULK1-mediated activation of 
VPS34-PI3K is accomplished through phosphorylation and release of Becn1 from its 
inhibitory interactions with the TAK-1-binding proteins (TABs) 2 and 3 (246, 247). The 
activating molecule in BECN1-regulated autophagy (AMBRA) protein is also 
phosphorylated by ULK1, leading to the recruitment of the E3 ubiquitin ligase TNF 
receptor-associated factor 6 (TRAF6) by Becn1 and AMBRA (248, 249). TRAF6 then 
ubiquitinates and stabilizes Becn1 and ULK1, enabling the progression of 
autophagosome formation (248, 249). This process is intersected by signaling events 
downstream of PRRs and cytokine receptors, enabling immunological control of 
autophagosomal machinery. Ligation of TLR4 triggers the interaction of the adaptor 
proteins MyD88 and Trif with Becn1, which disrupts the inhibitory interaction of Becn1 
with BCL2 (250). TLR4 signaling also initiates autophagy through activation of TRAF6, 
leading to the ubiquitination of Becn1 and ULK1 (251). Some NLRs, such as NOD2, also 
24 
 
initiate autophagy through RIPK2-mediated ubiquitination of ULK1 (252). Signaling 
through the IL-1 receptor (253) and the IFNγ receptor (254–257) by IL-1 and IFNγ also 
trigger autophagy in macrophages through interaction with TRAF6 or Becn1, 
respectively.  In contrast, the Th2 cytokines IL-4 and IL-13, along with IL-10 and IL-6, 
inhibit autophagy under certain circumstances (255, 258, 259). These examples illustrate 
the interconnected nature of PRR and cytokine receptor signaling and autophagosomal 
regulation. 
1c.ii. Host autophagy and defense against intracellular pathogens 
A requirement for host autophagy and autophagosomal machinery has been well-
elucidated in the context of intracellular bacterial infection (260). Autophagosomal 
capture and degradation provides a critical mechanism for the removal of intracellular 
microorganisms, and is termed xenophagy (260). The degradation of bacteria such as 
Listeria and Shigella, which routinely escape phagosomal incarceration, is dependent on 
autophagosomal capture (261–263). Cytosolic bacteria are targeted to forming 
autophagosomes through the actions of sequesteosome-like receptors (SLRs), which bind 
ubiquitinated bacteria and interact with membrane-bound LC3 on the inner 
autophagosomal membrane (261, 262, 264–266). In addition, a non-canonical autophagic 
pathway termed LC3-associated phagocytosis (LAP) is employed to expedite the 
degradation of phagocytosed bacteria (267, 268), as well as extracellular objects such as 
apoptotic cells (269), TLR-ligand-coated particles (267), and immune complexes taken 
up by FcγR-dependent endocytosis (268, 270). The involvement of LC3 conjugation and 
Becn1-VPS34 complexes in the formation of a single-membrane phagosome targets the 
contents for degradation in the same manner as traditional double-membrane 
autophagosomes, which mature through fusion with lysosomes (271).  
The importance of autophagy in defense against bacterial invasion is further 
evidenced by the variety of ways in which pathogens subvert or commandeer host 
autophagic machinery for their own ends. Many bacteria block the induction of 
autophagy or evade autophagosomal capture through the expression of proteins that 
interfere with autophagosomal targeting, formation, or maturation. For example, 
Salmonella avoid recognition by SLRs through expression of the deubiquitinase SseL, 
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which removes host ubiquitin tags utilized by SLRs to target bacteria to forming 
autophagosomes (272). Similarly, the Listeria proteins AktA and InIK interfere with 
ubiquitination through recruitment of cytosolic proteins to mask bacterial epitopes (262, 
263), while Shigella evades capture through expression of the epitope-masking protein 
IcsB (273). Other bacterial effector proteins, such as the Legionella virulence factor 
RavZ, directly target host autophagosome formation through the cleavage of ATG8 
homologs (274). Finally, the maturation of autophagosomes may be blocked by captured 
bacteria, as Listeria prevents autophagosomal acidification through the expression of the 
pore-forming protein listeriolysin O (275).  
In contrast to bacterial infection, cell survival through direct autophagic control of 
viral replication is largely restricted to neurotropic viruses such as Sindbis virus (276, 
277) and neurovirulent herpes simplex virus-1 (278), and is likely due to the irreplaceable 
nature of neurons. However, the importance of host autophagy to the limitation of viral 
replication is evidenced by the number of viral proteins which interfere with host 
autophagy, particularly by targeting Becn1. The herpes simplex virus 1 (HSV-1) 
virulence factor ICP34.5 inhibits host autophagy by binding Becn1 (278, 279), while the 
murine γ-herpesvirus 68 expresses M11, a viral homologue of BCL2, which inhibits 
Becn1-dependent autophagy (280). The influenza A M2 protein (281) and HIV protein 
Nef (282, 283) also bind Becn1 in order to prevent autophagosomal fusion with 
lysosomes. The virulence factors HIV-1 Nef, Hepatitis C virus NS3 and measles virus 
Mev3 were recently shown to interact with the autophagy factor immunity-related 
GTPase-family M (IRGM), although the functional consequences of these interactions 
have yet to be investigated (284). Interestingly, some evidence suggests that viruses such 
as poliovirus and HIV-1 may utilize autophagosomes as lipid-membrane scaffolds, 
thereby enhancing viral replication. Similarly, the induction of autophagy may function 
as a non-lytic mechanism for viral release, as the pharmacological stimulation of 
autophagy in cells infected with poliovirus (285) and HIV-1 (283) resulted in increased 
extracellular viral yields.  
A potential requirement for autophagy in cell-autonomous control of RSV 
replication has not been investigated. However, the process may be indirectly involved 
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through modulation of DC antigen presentation and pro-inflammatory cytokine 
production in response to infection. Indeed, recent studies conducted by our laboratory 
have demonstrated that DCs rapidly upregulate autophagosome formation upon detection 
of RSV (Figure 1-3). Moreover, autophagy facilitates DC maturation, cytokine 
production, and antigen presentation function in the context of RSV infection, and is 
required for the stimulation of IFNγ production from RSV-reactive T cells (230).  
1c.iii. Involvement of autophagy in DC function 
Autophagy has been recruited to facilitate several aspects of DC maturation in 
response to pathogen detection. The process of autophagy provides a mechanism for 
delivery of cytosolic peptides to MHC-I and MHC-II loading compartments, which are 
subsequently presented to CD4+ or CD8+ T cells, respectively. In addition, the 
sequestration and transport of cytoplasmic contents enables surveillance of the 
intracellular environment by endosomal TLRs, thereby facilitating rapid upregulation of 
innate cytokine production and surface expression of MHC-I/II and costimulatory 
molecules that are vital to the activation of T cells during antigen presentation. The 
process of autophagy may be especially critical to the immediate detection of RSV, as the 
virus infects through fusion with the plasma membrane rather than entering and escaping 
the endosomal pathway as many viruses do (1).   
Figure 1-3- Autophagosome formation in RSV-infected murine bone marrow-derived DC. Right inset 
shows double-membrane autophagosomes containing cytoplasmic material and rough ER (black arrows). 
27 
 
The presentation of foreign antigens by DCs in the context of MHC-I/II, along 
with costimulatory molecules and instructional innate cytokines, is required for the 
activation of CD4+ T helper cell-mediated immune responses to pathogens. Peptides are 
loaded onto MHC-II molecules within endosomes or MHC class II-containing loading 
compartments (MIICs), thereby stabilizing MHC-II for export to the cell surface (189). 
Within DCs in the steady state, MIICs receive continuous input from both endocytosis 
and autophagy, enabling the loading of intracellular self-peptides or extracellular antigens 
for presentation to CD4+ T cells (286–288). The contribution of autophagy to the cross-
presentation of cytosolic antigens via MHC-I is not as thoroughly investigated, but 
autophagy may contribute to the delivery of proteasome-degraded peptides to MHC-I-
containing compartments (289–291). DCs frequently obtain peptides destined for cross-
presentation from phagocytosed apoptotic cells, and autophagy in the peptide-donor cell 
prior to apoptosis contributes to this process (292, 293). 
Autophagosomal capture and delivery of intracellular pathogen-derived peptides 
is critical to CD4+ T cell activation during certain viral infections. Presentation of 
peptides from the Epstein Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1), a 
CD4+ T cell epitope consistently found in healthy carriers of EBV, requires autophagy in 
DCs (288, 294). The importance of DC-associated autophagy was demonstrated in vivo 
using mice selectively deficient in ATG5 in DCs, which showed decreased CD4+ T cell 
responses upon infection with HSV-1 (295). In addition, infection of DCs with HSV that 
lacked the Becn1-binding virulence factor ICP34.5 resulted in elevated CD4+ T cell 
responses in comparison to wild-type HSV (278). Further studies examining the ability of 
ATG5-deficient DCs to present extracellular peptides such as ovalbumin to ovalbumin-
responsive CD4+ T cells also found decreased T cell responses (295), suggesting that 
autophagy machinery also promotes the presentation of extracellular peptides to T cells. 
This requirement is not universal, however, as CD4+ T cell responses to influenza A-
infected DCs were unaltered by autophagy blockade (296).  
In addition to sequestering viral peptides for presentation to T cells, 
autophagosomal transport of viral nucleic acids to endosomal TLRs enables the rapid 
induction of pro-inflammatory cytokine production in response to infection. This was 
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first established in pDCs, which express TLR7 and require the autophagy protein ATG5 
to facilitate TLR7-dependent IFNα production in response to vesicular stomatitis virus 
(VSV) (297). Subsequent studies of human pDCs found a requirement for autophagy in 
the production of IFNα in response to HIV-1 (298) and the paramyxovirus Simian virus 5 
(299). Interestingly, treatment of macrophages or DCs with certain TLR ligands was 
reported to upregulate autophagosome formation, suggesting that TLRs and 
autophagosomal proteins cooperate in the response to detected pathogens. The 
upregulation of autophagy in macrophages was first noted upon treatment with the TLR4 
ligand lipopolysaccharide (LPS) (250), and subsequent studies found that this response is 
specific to agonists of TLR1/2, TLR3, TLR4, or TLR7 (300). Treatment of M. 
tuberculosis-infected macrophages with TLR4 or TLR7 ligands increased bacterial 
killing, suggesting that TLR-induced autophagy functions in clearance of intracellular 
pathogens (300). The upregulation of autophagy prior to microbial invasion facilitates the 
delivery of antimicrobial peptides to lysosomal compartments (301, 302), and may also 
mobilize autophagosomal proteins to forming phagophores, thereby expediting the 
acidification of pathogen-containing phagosomes (267). This TLR-induced mobilization 
of autophagy machinery ultimately contributes to enhanced antigen presentation and 
innate cytokine production by DCs in response to bacterial and viral infection (295, 303). 
1c.iv. Autophagic regulation of pro-inflammatory signaling 
In addition to promoting inflammatory responses to pathogens, the process of 
autophagy or autophagy proteins are implicated in the regulation of excessive 
inflammation. The first indication of this in chronic inflammatory human disease comes 
from genome-wide association studies, which revealed a correlation between SNPs in 
autophagy genes and risk of developing Crohns disease (304, 305), systemic lupus 
erythematosus (306–309), rheumatoid arthritis (310), and allergic asthma (311).  These 
findings support a clinically relevant requirement for autophagy in the control of 
inflammation. 
The proteins required for autophagosome formation, occasionally acting 
independently of the canonical autophagy pathway, are responsible for both direct and 
indirect suppression of certain pro-inflammatory complexes. The ATG5-ATG12 protein 
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complex negatively regulates the production of IFNβ by directly binding the CARD 
domains of the mitochondrial RLR adaptor protein IPS-1 and cytosolic RIG-I (312), 
while ATG9a suppresses IFNβ production in response to dsDNA (313). Similarly, the 
regulatory protein Rubicon binds CARD9, which is required for signaling downstream of 
RIG-I, thereby further inhibiting RIG-I-dependent IFNβ production (314). The 
mitochondrial protein NLRX1 simultaneously activates autophagy and inhibits RLR-
dependent type I interferon production (315, 316), which occurs through interaction of 
ATG5-ATG12 and ATG16L with the NLRX1-interacting protein TUFM (317). 
Moreover, in the absence of autophagy, a buildup of depolarized mitochondria increases 
the abundance of IPS-1 and ROS, both of which contribute to elevated RLR signaling 
and IFNβ production (318). The regulation of RLR signaling by autophagy may represent 
a feedback mechanism by which IFN signaling is limited after successful induction, 
thereby preventing excessive or prolonged IFNβ release (253, 266, 319).  
The negative regulation of IL-1β and IL-18 production, and therefore the 
development of IL-1β- and IL-18-dependent immunopathology, is also dependent on 
autophagy. IL-1β and IL-18 are produced in an inactive pro-form in response to NFκB 
activation, and require enzymatic cleavage by assembled cytoplasmic protein complexes 
called inflammasomes. A functional subunit of a multimeric inflammasome complex 
contains the enzyme pro-caspase-1, the adaptor protein ASC, and a cytosolic PRR such 
as AIM2 or one of the NLR family members (233). Autophagosomal regulation of 
inflammasome activity occurs on several levels: first, through the ‘housekeeping’ 
function of clearing the cytoplasm of protein aggregates and senescent mitochondria 
(234, 235); second, by sequestering and degrading pro-IL-1β and pro-IL-18 (320); and 
finally, through selective degradation of ubiquitinated inflammasome platforms (249).  
The requirement for basal autophagy in the prevention of sterile inflammation 
was first demonstrated in vivo through the observation of increased IL-1β and IL-18 
production by ATG16L-deficient mice in an experimental model of Crohns disease (321). 
Depolarized mitochondria accumulate in the absence of autophagy (234, 235), as 
autophagy is the only intracellular mechanism capable of sequestering and degrading 
mitochondria. Damaged mitochondria are a source of mitochondrial DNA (mtDNA) and 
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ROS, both of which function as endogenous inflammasome agonists (234, 235). The 
removal of compromised mitochondria is also critical to the limitation of inflammation 
during viral infection. A recent study utilizing a mouse model of influenza A infection 
found that mice deficient in NOD2 or its downstream target receptor-interacting protein 
kinase-2 (RIPK2) were hypersusceptible to infection, suffering increased lung pathology 
and mortality in comparison to WT mice (322). This was traced to a defect in 
mitochondrial clearance in the absence of RIPK2-mediated phosphorylation of ULK1. 
The failure to clear damaged mitochondria contributed to elevated release of ROS and 
increased inflammasome activation in RIPK2-deficient mice, ultimately resulting in 
greater IL-1β and IL-18 production in vivo (322). The importance of mitophagy likely 
extends to bacterial infection as well, as autophagy-deficient mice produce more IL-1β 
and suffer greater mortality in LPS-induced and cecal ligation-induced sepsis (235).  
The induction of autophagy further serves to negatively regulate inflammasome 
activity through direct removal of ubiquitinated inflammasome proteins and their 
substrates pro-IL-1α, pro-IL-1β, and pro-IL-18. In response to LPS treatment, 
macrophages sequester pro-IL-1β inside autophagosomes, with increased secretion of IL-
1β occurring upon treatment with the autophagy inhibitors 3-methyladenine (3-MA) or 
wortmannin (320, 321). Conversely, treatment with the autophagy inducer rapamycin 
promoted autophagosomal degradation of sequestered pro-IL-1β (320). A similar 
phenomenon was recently noted with respect to IL-1α secretion in response to LPS, 
although the production of IL-1α in this case was inflammasome-independent (323). In 
addition to promoting the degradation of inflammasome substrates, the process of 
selective autophagy facilitates the degradation of ubiquitinated inflammasome platforms 
(235, 249). The induction of AIM2 or NLRP3 inflammasomes in macrophages triggers 
autophagy, and is dependent on the expression of the inflammasome PRR (i.e. AIM2 or 
NLRP3) (235). Assembled inflammasomes undergo ubiquitination, and are targeted to 
nascent autophagosomes by the sequesteosome adaptor p62, which contains an ubiquitin-
binding domain and an LC3-interacting domain (321, 324). A similar regulatory 
mechanism has been proposed for the NLR NOD2, which forms inflammasomes in 
response to bacterial ligands (325) but also activates the autophagy-promoting RIPK2 
(322) and contributes to the spatial localization of autophagy machinery through 
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recruitment of ATG16L to sites of bacterial entry (326, 327). The simultaneous induction 
of autophagy and inflammasome assembly by the same cytosolic PRR provides a 
potential regulatory mechanism to limit pro-inflammatory IL-1β production.  
1c.v. ER stress-induced autophagy and inflammasome activation 
The endoplasmic reticulum is continually monitored in the steady state for signs 
of perturbation by several different ER-membrane-bound sensors, including inositol-
requiring protein 1α (IRE-1α), activating transcription factor 6 (ATF6), and protein 
kinase-like ER kinase (PERK) (236). Upon detection of the accumulation of misfolded 
proteins or depletion of ER calcium gradient, these sensors of ER stress activate the 
unfolded protein response (UPR). The UPR reduces the production of new proteins while 
upregulating gene expression of ER chaperone proteins, which assist in the folding of 
peptides.  Proteins that are improperly folded are removed through one of two ER-
associated degradation (ERAD) pathways, either by ubiquitin-proteasome ERAD I or 
autophagosome-lysosome ERAD II (328, 329). The latter pathway utilizes K63-specific 
mono/polyubiquitin tags on misfolded proteins, which are bound by cytosolic SLRs and 
shuttled to forming autophagosomes (330).  
Emerging research suggests that ER stress signaling may trigger autophagy-
mediated ER clearance as a cellular survival strategy, thereby expediting the removal of 
misfolded proteins and a return to homeostasis (331–334). In the presence of strong ER 
stressors, the NLRP3 inflammasome is activated via a mitochondrial-dependent 
mechanism, ultimately leading to IL-1β production (335, 336). NLRP3 and ASC are 
spatially recruited to mitochondria-associated ER membranes (MAMs) upon activation, 
possibly in response to the release of pro-inflammasome ROS from the mitochondria 
(234). Moreover, recent studies identified MAMs as the source of autophagosomal 
membranes, suggesting that autophagy occurs in immediate proximity to both the ER and 
mitochondria (337). This spatial arrangement may facilitate rapid clearance of damaged 
mitochondria and impacted ER (331), while also enabling autophagic control of IPS-1-
dependent signaling and IFNβ production (338).  
32 
 
Disruption of ER equilibrium may occur during viral infection through several 
different mechanisms. Rapid accumulation of viral proteins in the ER, especially those 
requiring glycosylation, may trigger ER stress (339–341).  In addition, virally-encoded 
viroporin proteins such as the rotavirus NSP4 protein (342) and picornavirus 2B proteins 
(343) depolarize calcium differentials in the ER, which can trigger ER stress (344). The 
ER may be further perturbed by viral utilization of ER replication complexes, and ER 
membrane as source-membrane for newly-synthesized virions (236). Interestingly, RSV 
infection was recently shown to trigger IRE-1α and ATF6 signaling, with blockade of 
IRE-1α signaling leading to enhanced viral replication (345). The RSV SH protein was 
recently identified as a viroporin, expression of which was required for RSV-induced IL-
1β production by human bronchial epithelial cells (138). However, any potential 
connection between ER stress, inflammasome activation, and autophagic control of IL-1β 
in the context of RSV infection remains to be explored. 
1d. Summary of rationale and specific aims 
Respiratory syncytial virus (RSV) is a ubiquitous human pathogen that produces 
severe lower respiratory disease in vulnerable individuals, characterized by lung 
infiltration of innate immune cells and a Th2-skewed adaptive immune response leading 
to excessive mucus production. RSV-associated bronchiolitis remains the leading cause 
of hospitalization among infants in the United States, and is responsible for considerable 
morbidity among patients who are elderly, immune compromised, and those with 
underlying chronic pulmonary illness. Hospitalization due to RSV in infancy is also 
strongly correlated with development of recurrent wheezing later in childhood, 
suggesting that infection causes lasting alteration of the lung immune environment and 
predisposition to chronic disease development.  
Pulmonary dendritic cells (DCs) direct innate and adaptive immune responses to 
viral pathogens through secretion of pro-inflammatory cytokines and type I interferon 
(IFN), as well as through activation of antiviral T cell responses in lung-draining lymph 
nodes. Signaling through the RNA-sensing endosomal toll-like receptors (TLR) -3 and -7 
is required for robust production of type I IFN and antigen presentation function by DCs 
during viral infection. As RSV infects target cells through membrane fusion rather than 
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through endocytosis, an alternative method of delivery of viral antigens to endosomal 
compartments is necessary for rapid detection of viral RNA. In agreement with other 
studies of virally-infected cells, work conducted by our laboratory has shown that 
macroautophagy (autophagy) modulates TLR-dependent maturation and antigen-
presenting cell (APC) function by RSV-infected DCs. 
Autophagosome formation is a conserved intracellular process by which cytosolic 
constituents are enveloped in a double-walled membrane and degraded by fusion with 
lysosomes. Moreover, autophagy within APCs facilitates MHC class II peptide loading 
and intracellular TLR signaling through acquisition and delivery of cytoplasmic viral 
proteins and nucleic acids to acidified endosomes. The autophagic pathway and its 
constituent proteins are conversely known to antagonize the assembled NLRP3 
inflammasome and its substrate pro-IL-1β in both epithelial and myeloid immune cells, 
suggesting a potential dual role of autophagy as a negative regulator of inflammatory 
signaling during RSV infection. As the clinical manifestations of severe RSV infection 
are linked to aberrant innate and T cell cytokine production, we hypothesize that 
autophagy proteins promote the effective induction of an antiviral immune response 
and clearance of RSV by facilitating DC maturation, while simultaneously 
minimizing excessive pulmonary inflammation through antagonism of 
inflammasome-mediated IL-1β secretion. These studies will utilize human RSV Line-
19, originally isolated from a hospitalized infant, and will be conducted in vitro and in a 
clinically relevant mouse model. This work will shed light on the basic mechanisms by 
which DCs orchestrate innate and acquired immune responses to RSV, which may have 
significant therapeutic implications for human disease.  
We will first examine the requirement ofATG6/Becn1 in DC-mediated 
induction of antiviral adaptive immune responses to RSV in vivo. We hypothesize 
that impaired autophagy-dependent DC maturation and innate cytokine production in 
Becn1 haploinsufficient (Becn1
+/-
) mice will result in an attenuated antiviral T cell 
response, decreased viral clearance, and increased lung pathology upon RSV infection. 
Results show that RSV-infected Becn1
+/-
 mice develop Th2 cytokine-associated mucus 
production and eosinophil infiltration within the lungs, while RSV-infected Becn1
+/-
 DCs 
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elicited Th2 cytokine production from co-cultured CD4+ T cells. Sensitization of WT 
mice with RSV-pulsed Becn1
+/-
 DCs recapitulated the Th2 pathology observed in 
Becn1
+/-
 mice upon RSV challenge, supporting the importance of Becn1-dependent 
autophagy in RSV-infected DC in vivo. 
We will next assess the requirement of ATG8/LC3b in innate and adaptive 
immune responses to RSV. We hypothesize that impaired autophagy induction in LC3b-
deficient (LC3b
-/-
) mice will result in an altered antiviral T cell response and increased 
lung pathology upon RSV infection. Results show that LC3b
-/-
 mice develop IL-17-
associated lung mucus production and neutrophil infiltration upon RSV infection, while 
RSV-infected LC3b
-/-
 DCs secrete IL-6 and IL-23, and elicit increased IL-17a production 
from co-cultured CD4+ T cells. Additionally, LC3b
-/-
 lung epithelial cells produce 
increased amounts of IL-1β and IL-6 in response to RSV, with epithelial cell cytokine 
production contributing to Th17-dependent lung neutrophilia and mucus production. IL-1 
receptor antagonist treatment reduced Th17 lung pathology, identifying IL-1R signaling 
as a driver of Th17 responses to RSV. 
Finally, we will investigate a requirement for LC3b expression in the control 
of ER stress signaling-dependent IL-1β production by RSV-infected cells. We 
hypothesize that autophagy deficiency in LC3b
-/- 
epithelial cells will promote ER stress 
signaling-dependent inflammasome activation and concomitant IL-1β secretion upon 
Figure 1-4 – Schematic representation of autophagy-mediated promotion of DC-mediated elicitation of Th1-
polarized CD4+ T cell responses to RSV, and autophagy-mediated regulation of lung pathology-inducing 
cytokine IL-1β.  A) Cytosolic viral peptides and RNA are captured by autophagosomes and fuse with lysosomes, 
thereby facilitating endosomal TLR activation, innate cytokine production, and upregulation of costimulatory 
molecules (B). This process promotes the production of IL-12, which polarizes CD4+ T cells towards a protective Th1 
phenotype (C). D) In addition, autophagy suppresses NLRP3 inflammasome activation and production of its substrate 
IL-1β through sequestration of damaged mitochondria, and/or through direct removal of inflammasomes and pro-IL-
1β. In the absence of autophagy, IRE-1α-mediated mitochondrial ROS/mtDNA release promotes NLRP3 
inflammasome activation and IL-1β secretion, ultimately contributing to the development of lung pathology in 
response to RSV. 
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RSV infection. Results demonstrate that LC3b
-/-
 epithelial cells increase signaling 
through the ER stress sensor IRE-1α upon RSV infection, while treatment with an 
inhibitor of IRE-1α attenuated caspase-1 cleavage and IL-1β secretion. These results 
implicate IRE-1α signaling and its control through an LC3b-dependent mechanism in 
driving excessive inflammasome activation and IL-1β secretion during RSV infection. 
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Chapter 2 – Autophagy-inducing protein Beclin-1 in dendritic 
cells regulates CD4 T cell responses and disease severity during 
respiratory syncytial virus infection 
2a. Abstract 
Recent work has demonstrated the importance of macroautophagy in dendritic 
cell (DC) maturation and innate cytokine production upon viral infection through 
delivery of cytoplasmic viral components to intracellular toll-like receptors. To study the 
functional consequences of impaired autophagosome formation during a Respiratory 
Syncytial Virus (RSV) infection, mice harboring significant autophagy defects due to 
Beclin-1 haploinsufficiency (Becn1
+/-
) were used. Upon RSV infection in vivo, lungs of 
Becn1
+/-
 mice showed increased Th2 cytokine production, mucus secretion, and lung 
infiltration of eosinophils and inflammatory DCs.  While isolated airway epithelial cells 
from Becn1
+/-
 mice demonstrated little change compared to Wild-type, Becn1
+/-
 
pulmonary and bone marrow-derived DCs (BMDCs) showed decreased expression of 
MHC-II and innate cytokine production upon RSV infection.  Further examination 
indicated that Becn1
+/-
 DC stimulated less IFNγ and IL-17 production by co-cultured 
CD4+ T cells and increased Th2 cytokine production in comparison to wild-type 
controls.  Finally, adoptive transfer of RSV-infected Becn1
+/-
 DCs into the airways of 
wild-type mice produced severe lung pathology and increased Th2 cytokine production 
upon subsequent RSV challenge compared to wild-type DC transfer controls. These 
results indicate a critical role of autophagy in dendritic cells during pulmonary viral 
infection, facilitating appropriate antiviral adaptive immune responses. 
2b. Introduction 
Respiratory viral infections are associated with significant morbidity and 
mortality in susceptible patient populations, outcomes primarily linked to inappropriate 
inflammatory and immune responses that compromise lung function (55, 56). Respiratory 
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syncytial virus (RSV) is a single-stranded RNA virus of the paramyxoviridae family, 
with a double-stranded RNA intermediate (40). RSV is a ubiquitous human pathogen that 
predominantly causes mild respiratory tract infection, yet it remains one of the leading 
causes of respiratory infection-related hospitalization worldwide (4, 5, 346). Vulnerable 
individuals such as infants, the elderly, or the immunosuppressed often develop severe 
symptoms such as bronchiolitis and pneumonia, characterized by mucus secretion and 
pulmonary infiltration of monocytes and granulocytes (40). In addition, hospitalization 
due to RSV in infancy is associated with an increased risk of developing allergic asthma 
and recurrent wheezing later in life (61, 62). The epidemiological evidence of subsequent 
immune alteration after RSV infection, combined with the complex nature of host and 
viral factors contributing to disease pathogenesis, underscore the need to understand the 
host response to RSV and its contribution to viral clearance, as well as to immune-
mediated lung pathology.  
Within the lung environment, dendritic cells (DCs) direct innate and adaptive 
immune responses to viral pathogens through secretion of pro-inflammatory cytokines 
and type I interferon (IFN), as well as through migration and antigen presentation to T 
cells in lung-draining lymph nodes. DC activation is accomplished through detection of 
viral antigens by pattern-recognition receptors (PRRs) such as PKR, RIG-I, and both 
MyD88-dependent and TRIF-dependent toll-like receptors (TLRs) (139). Activation of 
RNA-sensing intracellular TLRs such as TLR3 and TLR7 is required for robust 
production of type I IFN and APC function in virally infected plasmacytoid and myeloid 
DC (347, 348). Acquisition of viral antigens may be accomplished through phagocytosis 
of virally-infected cells, yet recent work conducted by ourselves and others suggests that 
the intracellular process of macroautophagy (autophagy) within virally-infected DCs 
functions as an important driver of DC maturation and pro-inflammatory cytokine 
production (230, 297).  This process may be especially important during RSV infection, 
as RSV directly enters the cytoplasm via membrane fusion (349), thus requiring delivery 
of cytosolic viral nucleic acid to endosomal TLRs (134, 349). 
Autophagy is a highly conserved process through which cytoplasmic contents are 
enveloped in a double-walled membrane and degraded upon fusion with lysosomes. 
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Autophagosome formation is initiated in mammalian cells by release of ATG6/Beclin-1 
(Becn1) from Bcl-2, enabling formation of the Becn1-containing VPS34-PI3K complex 
that is required for generation of pre-autophagosome structures (350). Becn1 is a frequent 
target of viral subversion, attesting to the importance of autophagy in clearance of 
intracellular pathogens from infected host cells (351). In addition, autophagy modulates 
several important functions within professional antigen-presenting cells (APCs) by 
enabling cytoplasmic antigen capture and MHC-mediated presentation to T cells (287, 
352), by regulating inflammasome activity and IL-1β secretion (235, 249), and by 
promoting TLR-dependent DC maturation and type I IFN production through delivery of 
TLR ligands to endosomes (353). Furthermore, TLR ligation upregulates autophagosome 
formation through TRAF6-dependent ubiquitination and release of Becn1 from BCL-2, 
potentially serving as a positive regulation mechanism of TLR signaling (354). While the 
functions of autophagy in APCs infected in vitro have been examined, studies of 
autophagy in vivo have largely focused on host protection during bacterial infection, or 
host protection from encephalitis upon infection with neuropathogenic viruses (278, 355, 
356). While viral subversion of autophagy and decreased CD4+ T cell responses to 
neurovirulent HSV-1 were recently elucidated (278, 352, 356), the role of autophagy in 
promoting DC maturation during pulmonary viral infection and the impact on CD4+ T 
cell responses is poorly understood.  
Our laboratory recently reported that TLR-dependent innate cytokine production 
and maturation of RSV-infected DCs was attenuated upon blockade of autophagy, 
resulting in decreased production of IFNγ and IL-17a in co-cultured CD4+ T cells (230).  
In order to examine the importance of autophagosome formation during RSV infection in 
vivo, we used Becn1
+/- 
mice that harbor defects in the upregulation of autophagosome 
formation upon stimulation (353). Altogether, these studies demonstrated the role of 
autophagy within DCs to facilitate priming of a robust antiviral adaptive immune 
response to RSV, as well as in the limitation of excessive pathology during pulmonary 
infection.  The impact of these findings may have significant therapeutic implications for 
severe clinical disease and may contribute strategies for viral vaccine development. 
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2c. Materials and methods 
Mice  
Female C57Bl/6J, BALB/cJ, and B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II) transgenic mice 
were purchased at 6-7 weeks of age from The Jackson Laboratory (Bar Harbor, ME). 
Becn1
+/-
 mice were originally obtained from Z. Yue (353), and a breeding colony was 
subsequently established at the University of Michigan (Ann Arbor, MI). D011.10 mice 
were bred in-house at the University of Michigan. All work involving animals was 
conducted in compliance with University of Michigan Committee on Use and Care of 
Animals policy.  
Respiratory Syncytial Virus 
Our laboratory uses antigenic subgroup A, Line 19 RSV, originally obtained from a sick 
infant at the University of Michigan Hospital System. This isolate has been shown in 
animal models to mimic human infection by eliciting airway mucus production upon 
inoculation with 1 x 10
5
 pfu RSV (357). Mice were infected intratracheally with 1 x 10
5
 
pfu RSV. 
Quantitative PCR  
RNA was isolated from cell cultures and lung tissue using TRIzol, according to 
manufacturer’s instructions (Invitrogen). 5μg of RNA was then reverse-transcribed to 
determine cytokine gene expression using pre-developed TaqMan Gene Expression 
Assay primer/probe sets and analyzed using an ABI Prism 7500 Sequence Detection 
System (Applied Biosystems, Foster City, CA). Transcription levels of muc5ac, gob5, 
ifnb, and RSV-G, -F, and –N proteins were assessed using custom primers as previously 
described (155). Gene expression was normalized using GAPDH expression as an 
internal control, and fold change values were calculated relative to an uninfected or wild-
type control group assigned an arbitrary value of 1. 
Dendritic cell culture 
BMDC were cultured from whole bone marrow, obtained from WT C57Bl/6 mice, 
Becn1
+/-
 mice, or WT littermates as indicated. Bone marrow cells were seeded into tissue 
culture flasks containing RPMI 1640-based complete media supplemented with 20ng/ml 
GM-CSF (R&D systems, Minneapolis, MN). Cells were fed on day 3 and 5, and 
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harvested on day 7. On day 7, cells were ≥85% CD11b+ CD11c+ BMDC by flow 
cytometric analysis.  
Pulmonary CD103+ and CD11b+ DC were obtained from lungs and bronchi of C57Bl/6 
mice by enzymatic digestion, through modification of previously-published methods 
(358). Minced tissue was incubated in RPMI-1640 with 200μg/ml Liberase TM (Roche 
Applied Science, Indianapolis, IN) and 200 U/ml DNase I (Sigma-Aldrich) for 45 
minutes at 37°C, drawn through an 18-gauge needle/10cc syringe, and filtered through 
40μm nylon mesh. The cell suspension was enriched for CD11c+ cells using anti-mouse 
CD11c microbeads and magnetic column separation (Miltenyi Biotec, Auburn, CA), then 
stained with PE-conjugated anti-CD11b and APC-conjugated anti-CD103 antibodies 
(eBioscience, San Diego, CA). DC subsets were sorted using an iCyt Synergy 3200 
fluorescence-activated cell sorter (iCyt, Champaign, IL). 
Alveolar Epithelial Cell culture  
Whole lungs of naïve mice were digested in Dispase (BD Biosciences), filtered through 
25μm mesh, and depleted of immune cells through labeling with biotinylated antibodies 
to CD16/32 and CD45 (BD Pharmingen), followed by labeling with anti-biotin 
microbeads and passage through a MACS column (Miltenyi Biotec). Depleted cell 
suspensions were adherence-purified overnight in DMEM-based complete media, and 
non-adherent cells cultured for 4 days in complete media within fibronectin-coated wells, 
yielding ≥90% e-cadherin positive cells. Cultures were RSV-infected at 1:1 MOI. 
CD4+ T cell isolation and DC-T cell co-culture   
RSV-responsive CD4+ T cells were isolated from mediastinal and cervical lymph nodes 
of C57Bl/6 mice infected 8 days previously with 1 x 10
5
 pfu RSV. Ovalbumin-responsive 
T lymphocytes were isolated from minced spleens from OT-II or D011.10 transgenic 
mice as indicated. Lymph nodes or minced spleens were forced through a 40μm nylon 
strainer, then CD4+ T cells were isolated using magnetic bead selection, using a negative 
selection protocol yielding >95% pure CD4+ T cells (Miltenyi Biotec, Auburn, CA). T 
cells were subsequently plated at 5 x 10
5
 cells per well in 96-well cell culture plates, on 
top of 5 x 10
4
 DC treated two hours previously with 1:1 MOI RSV. Experiments 
conducted with OT-II or D011.10 T cells were treated with 200μg/ml whole ovalbumin 
protein as indicated. Co-cultures were incubated for 24 hours for mRNA analysis, or 48 
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hours for cell supernatant cytokine analysis on the BioRad Bioplex 200 system, 
according to manufacturer’s protocol. Custom kits containing Ab-coated beads for mouse 
IL-4, IL-5, IL-13, IL-17a, and IFNγ were used to assay cytokine concentration (BioRad). 
Flow Cytometry  
Right lungs of control and RSV-infected mice were digested enzymatically in RPMI-
1640 complete media containing 1mg/ml Collagenase A (Roche Applied Science, 
Indianapolis, IN) and 30μg/ml DNase I (Sigma). LDLN were forced through a 40μm 
nylon strainer. Cells were stained with Live/Dead Fixable Yellow (Invitrogen) followed 
by appropriate antibodies as indicated. Analysis was performed using FlowJo software 
(Treestar Inc, Ashland, OR). 
Confocal Microscopy  
BMDCs were cultured as described, then plated in Labtek chamber slides (Thermo Fisher 
Scientific). Cells were treated as indicated, then fixed in 4% paraformaldehyde for 20 
minutes. Cells were blocked for one hour at room temperature in PBS containing 5% 
normal goat serum and 0.1% Tween-20, and stained with DyLight 550-conjugated anti-
ATG5 antibodies (Novus Biologicals, Littleton, CO). Pro-long Gold anti-fade reagent 
plus DAPI was added (Invitrogen), and cells were imaged on a Nikon A1 Confocal Laser 
Microscope system under 60x oil immersion, using NIS Elements acquisition software 
(Nikon Instruments Inc.). Maximum intensity projection images were created from Z-
stack images using ImageJ software (NIH). 
Statistics  
Data was analyzed and graphs generated using GraphPad Prism software. Statistical 
significance was assessed by one-way ANOVA, followed by Bonferroni post-test to 
obtain p values. Significant differences were regarded as p≤ 0.05. 
2d. Results 
2d.i. Becn1
+/-
 mice show increased lung pathology upon RSV infection 
Homozygous deletion of many autophagy genes, including Becn1, results in early 
embryonic or neonatal lethality in mice (353, 359). In order to assess the importance of 
autophagosome formation during RSV infection in vivo, we chose to use Becn1
+/-
 mice, 
which are viable but show defects in autophagosome formation (353). Becn1
+/-
 and wild-
type (WT) littermate mice were infected with RSV and sacrificed at day 8 post-infection 
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to assess lung pathology. Histological examination of paraffin-embedded lung sections 
revealed increased peribronchial inflammation, goblet cell metaplasia, and occlusion of 
airways by mucus and cellular debris in RSV-infected Becn1
+/-
 mice (Figure 2-1A). Flow 
cytometric analysis of single-cell suspensions obtained from collagenase-digested lung 
tissue revealed increased numbers of eosinophils and DCs within the lungs of Becn1
+/-
mice (Figure 2-1B).  Additionally, lung-draining lymph node (LDLN) cultures prepared 
from RSV-infected Becn1
+/-
 mice secreted significantly greater amounts of Th2 
cytokines, and  significantly less IFNγ and IL-17a production upon restimulation with 
RSV ex vivo when compared to LDLN from WT mice (Figure 2-1C). As lung 
Figure 2-1 - Beclin-1+/- mice show increased pulmonary immune infiltration and pathology upon RSV infection. 
(A) Lung sections from RSV-infected Beclin-1+/- mice or WT littermate controls 8 days post-infection, stained with 
either haematoxylin and eosin (H&E, top panels) or haematoxylin and periodic acid schiff (H&PAS, bottom panels) 
stain. Arrow indicates apoptotic cell debris within airway mucus plug (B) Total numbers of lineage-positive immune 
cells obtained from collagenase-digested lungs of Beclin-1+/- or WT mice, 8 days post-RSV infection. (C) Lung-
draining lymph nodes of Beclin+/- or WT mice, 8 days post-RSV infection, were dissociated into a single cell 
suspension and restimulated in culture with RSV. Cytokine concentrations in culture supernatants were assayed using a 
Bioplex system. Lung mRNA expression of CCL20  and  CCL11/eotaxin (D) 6 days post-RSV infection, and (E) the 
mucus-associated genes muc5ac and gob5 8 days post-infection, was obtained using quantitative real-time PCR (qPCR) 
and compared to naïve controls. (F) Percentage of total lung CD8α+ T cells expressing Granzyme B by intracellular 
staining and flow cytometry, obtained from collagenase-digested lungs 8 days post-RSV infection. (G) Lung mRNA 
expression values of RSV-G, -F, and –N transcript was obtained by qPCR 8 days post-infection. Fold change was 
calculated relative to WT, RSV-infected lungs. Data are representative of three independent experiments, with four to 
six mice per group. Error bars represent SEM. *p<0.05, **p<0.01, ***p<0.001. 
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recruitment of eosinophils and DCs during RSV infection was shown to be respectively 
dependent on secretion of CCL11/eotaxin (360) and CCL20 (226), these chemokines 
were assessed by qPCR and were found to be significantly increased in lungs of RSV-
infected Becn1
+/-
mice (Figure 2-1D). Increased mucus secretion within the lungs was 
observed by periodic acid schiff (PAS) staining of lung sections, while mRNA transcript 
levels of mucus-associated genes muc5ac and gob5 were significantly elevated in lungs 
of Becn1
+/-
mice (Figure 2-1A, Figure 2-1E). Interestingly, overall numbers of CD8a+ T 
cells did not differ at day 8 post-infection (Figure 2-1B), yet fewer CD8a+ T cells from 
Becn1
+/-
 lungs expressed the cytotoxic protease Granzyme B when compared to lungs 
from WT mice (Figure 2-1F). Finally, qPCR measurement of RSV-G, -F, and -N mRNA 
within lung tissue showed significantly increased viral mRNA expression in infected 
Becn1
+/-
 mice in comparison to RSV-infected WT littermates, suggesting increased viral 
replication (Figure 2-1G). These data suggest that Becn1
+/-
 mice are impaired in their 
ability to mount an effective antiviral adaptive immune response upon RSV infection, 
instead producing increased Th2 cytokine-associated lung pathology in vivo. 
2d.i. Becn1
+/-
 pulmonary DCs show impaired maturation upon RSV infection 
Autophagosome formation and maturation is known to be critical in mediating 
innate viral recognition and presentation of cytoplasmic viral antigens by DCs to T cells 
(351). In agreement, previous studies conducted by our laboratory found that blockade of 
autophagosome formation within DCs resulted in impaired surface expression of MHC 
class II and costimulatory molecules CD80/CD86 upon RSV infection in vitro (230).  We 
therefore examined the numbers and maturation status of DCs that were present in the 
lungs and LDLN of RSV infected Becn1
+/-
 mice and compared them to control tissues 
from RSV-infected WT mice. Pulmonary DC subsets in enzyme-digested lungs and 
LDLN were identified and quantified by flow cytometry (361), and revealed sharply 
increased numbers of CD11c+ MHC-II
high
 CD11b
high
 DCs (CD11b+ DCs) in lungs of 
infected Becn1
+/-
 mice, with no significant differences detected in numbers of CD11c+ 
MHC-II
high
 CD11b
low
 CD103+ intraepithelial DCs (CD103+ DCs)  (Figure 2-2A, Figure 
2-2B). Due to increased cellularity, greater numbers of both CD11b+ DCs and CD103+ 
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DCs were recovered from the LDLN of infected Becn1
+/-
mice, although relative 
percentages did not reach significance (Figure 2-2C, Figure 2-2D). The lungs of RSV-
infected Becn1
+/-
 mice contained a significantly greater number of CD45+ cells (Figure 
2-2E), while the mediastinal lymph nodes recovered from infected Becn1
+/-
 mice 
appeared larger than those from WT littermates. This was reflected in significantly higher 
total numbers of lymph node cells recovered per mouse (Figure 2-2F). Further 
examination of surface molecule expression of CD11b+ DCs in the lungs revealed that a 
large percentage were FcεRIα+ Ly6C+ inflammatory DCs, and were present in greater 
Figure 2-2 - Beclin-1+/- mice recruit greater numbers of DCs displaying decreased MHC class II expression upon 
RSV infection. Lungs and lung-draining lymph nodes (LDLNs) were harvested 8 days post-RSV infection, and tissues 
from Beclin-1+/- mice were compared to those from WT mice using flow cytometry. (A) Representative flow plots of 
CD11b+ and CD103+ DCs from collagenase-digested lungs of Beclin-1+/- or WT littermate mice. Total numbers of 
CD11b+ and CD103+ DCs (B) were calculated using percentages and total cell counts within lungs. (C) Representative 
flow plots of CD11b+ and CD103+ DCs in single-cell preparations of LDLNs of Beclin-1+/- or WT littermate mice. 
Total numbers of CD11b+ and CD103+ DCs (D) were calculated using percentages and total cell counts within 
LDLNs. (E) Total CD45+ cell counts from lungs, (F) LDLNs, and (G) lung inflammatory CD11b+ DCs co-staining 
with FcεRIα+ (clone MAR-1) and Ly6C+ were calculated by flow cytometry. (H) Median fluorescence intensity (MFI) 
of MHC-II surface staining on CD11b+ and CD103+ DCs from LDLNs. Data are representative of at least three 
independent experiments, with four to six mice per group. Error bars represent SEM. *p<0.05, **p<0.01, ***p<0.001. 
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numbers in lungs of RSV-infected Becn1
+/-
 mice (Figure 2-2G). Finally, assessment of 
DCs within the LDLNs revealed decreased MHC-II expression on both CD11b+ DCs and 
CD103+ DCs (Figure 2-2H), with no differences in expression of co-stimulatory 
molecules CD80, CD86, or CD40 in comparison to infected WT mice (data not shown).   
In addition to modulating DC maturation, autophagy proteins have been shown to 
regulate cytokine production in virally-infected non-hematopoietic cells through delivery 
of viral antigens to intracellular TLRs, as well as through antagonism of signaling by 
cytosolic pattern recognition receptors such as RIG-I (362). As RSV predominantly 
infects the respiratory epithelium and intraepithelial DCs (363), we investigated innate 
cytokine responses of both RSV-infected epithelial cells and pulmonary DCs from 
Becn1
+/-
 mice. Pro-inflammatory cytokine production by RSV-infected Becn1
+/-
 primary 
airway epithelial cell cultures (AECs) revealed no significant differences in comparison 
to WT cultures when assessed by qPCR 24 hours post-infection (Figure 2-3A). Similarly, 
both WT and Becn1
+/-
 RSV-infected AECs showed no significant upregulation of key 
autophagy genes 24 hours post-RSV infection (Figure 2-3B). Further examination of 
autophagy induction through ATG5 punctate staining and confocal microscopy, as well 
as through accumulation of membrane-bound LC3-II by immunoblotting, revealed no 
significant changes in RSV-infected AECs compared to uninfected controls (data not 
shown).  
In contrast, both CD11b+ and CD103+ pulmonary DCs from naïve Becn1
+/-
 lungs 
showed reduced innate cytokine production upon ex vivo RSV infection (Figure 2-3C).  
Pulmonary DCs from WT and Becn1
+/-
 mice showed differential upregulation of 
autophagy genes upon infection, as RSV-infected Becn1
+/-
 DCs failed to upregulate 
expression of ATG5, ATG6, and ATG7 in comparison to RSV-infected WT DCs (Figure 
2-3D). Importantly, as a measure of antigen presentation function, RSV-infected Becn1
+/-
 
DCs co-cultured with CD4+ OT-II T cells elicited less IFNγ and IL-17a production in 
comparison to WT controls (Figure 2-3E).  These results suggest that while Becn1
+/-
 mice 
appear to have no innate defect in cytokine production by epithelial cells or CD4+ T 
cells, Becn1
+/-
 pulmonary DCs are impaired in innate cytokine production and antigen 
presentation in response to RSV infection.  
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Controlled regulation of Becn1 expression has been documented during T cell 
development and activation, although the functional significance of this observation is 
not known (364). To ensure that Becn1
+/-
 CD4+ T cells do not possess an intrinsic 
cytokine production deficiency or Th2 bias upon activation, we stimulated purified 
splenic CD4+ T cells from naïve Becn1
+/-
 or WT littermate control mice with antibodies 
to CD3 and CD28. Measurement of cytokine secretion in culture supernatants across a 
five-day time course revealed no significant differences in production of IL-5, IL-13, IL-
17a, or IFNγ by Becn1+/- T cells (Figure 2-3F). 
Figure 2-3 - Beclin-1+/- lung epithelial cells are competent in innate cytokine responses to RSV infection, while 
pulmonary DCs are impaired in innate cytokine production, autophagy gene expression, and antigen 
presentation upon RSV infection. (A) Cytokine production and (B) autophagy gene expression by Beclin-1+/- or wild-
type mouse primary alveolar epithelial cells was assessed by qPCR 24 hours post-RSV infection.  (C-E) Pulmonary 
DCs were fluorescently labeled and flow-sorted from collagenase-digested lungs of naïve Beclin-1+/- or wild-type mice, 
and infected with RSV at 1 DC: 1 pfu (1:1 MOI). Innate cytokine production and autophagy gene expression by 
CD11b+ lung DCs or CD103+ DCs (C) was assessed at 24 hours post-RSV infection by qPCR. Autophagy gene 
expression by CD11b+ DCs or CD103+ DCs (D) was measured by qPCR at 24 hours post-infection. Cytokine 
production by purified splenic CD4+ OT-II T cells, co-cultured with CD11b+ lung DCs or CD103+ DCs (E) treated 
concurrently with RSV and 200μg/ml whole ovalbumin protein, was assessed by qPCR at 24 hours. Data are 
representative of at least two independent experiments, with at least four replicates per group. Error bars represent 
SEM. (F) WT and Beclin-1+/- purified CD4+ splenocytes were cultured with antibodies to CD3 and CD28. 
Supernatants were assayed by Bioplex.  *p<0.05, **p<0.01. 
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2d.ii. Becn1
+/-
 BMDCs are deficient in innate cytokine production and fail to mature 
upon RSV infection 
Previous work conducted by our laboratory demonstrated that TLR-dependent DC 
maturation and innate cytokine production in response to RSV is dependent on autophagy 
(230). Having obtained similar results for lung-derived Becn1
+/-
 DCs infected with RSV 
ex vivo, we utilized bone marrow-derived DCs (BMDCs) cultured from Becn1
+/-
 mice to 
further study the impact of Becn1 insufficiency on the upregulation of autophagy and on 
DC maturation. Examination of punctate ATG5 staining by confocal microscopy, which 
identifies nascent autophagosomes (350), confirmed a defect in autophagosome 
formation within RSV-infected Becn1
+/-
 BMDCs (Figure 2-4A, Figure 2-4B). Becn1
+/-
 
BMDCs similarly failed to upregulate autophagy gene mRNA expression in response to 
RSV (Figure 2-4C).  
Becn1
+/-
 DC maturation was next examined by assessing costimulatory molecule 
expression and innate cytokine production upon RSV infection.  Analysis of surface 
staining of RSV-infected BMDCs by flow cytometry revealed that while WT BMDCs 
upregulated surface expression of MHC-II and CD80/86 co-stimulatory molecule 
expression in response to RSV infection, Becn1
+/-
 BMDCs only weakly upregulated 
MHC-II expression and did not increase expression of CD80 or CD86 above the levels of 
uninfected controls (Figure 2-4D). In addition, qPCR of RSV-infected Becn1
+/-
 BMDCs 
revealed significantly less type I interferon and pro-inflammatory cytokine production in 
comparison to WT controls (Figure 2-4E). These results confirm our previous findings 
that support the role of autophagy in promoting DC maturation, as Becn1
+/-
 DCs fail to 
upregulate autophagosome formation, MHC-II expression, and produce innate cytokines 
upon RSV infection.  
We next sought to verify the modulatory role of autophagy in altered cytokine 
production by Becn1
+/-
 DCs. In agreement with our previous findings (230), induction of 
autophagy in WT BMDCs through amino acid starvation prior to RSV infection 
synergistically increased IFNβ and IL-6 production in comparison to RSV infection 
alone, as well as IL-12p40 and IL-1β to a lesser extent (Figure 2-4F). In contrast, 
Becn1
+/-
 BMDCs produced significantly less of these cytokines in response to either RSV 
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infection or starvation-induced autophagy prior to RSV infection, with no synergistic 
increase in cytokine production observed with starvation (Figure 2-4F).   
Figure 2-4 - Altered autophagosome formation, autophagy-dependent innate cytokine production, and 
maturation in response to RSV infection by Beclin-1+/- DCs. (A) Autophagosome formation by Beclin-1+/- or WT 
bone marrow-derived DCs two hours post-RSV infection (1:1 MOI) was measured by punctate ATG5 staining and 
confocal microscopy, quantified in (B). (C)  Autophagy gene expression by Beclin-1+/- or WT BMDCs was assessed 24 
hours post-RSV infection. (D) Surface costimulatory marker expression by Beclin-1+/- or WT BMDCs was measured 
by flow cytometry, 24 hours post-RSV infection. (E) Innate cytokine production by Beclin-1+/- or WT BMDCs, 
measured by qPCR 24 hours post-RSV infection. (F) Innate cytokine production by Beclin-1+/- or WT BMDCs, 
incubated in media or HBSS for two hours followed by 24 hour RSV infection, was assessed by qPCR. Data are 
representative of at least two independent experiments, with at least four replicates per group. Error bars represent 
SEM. *p<0.05, **p<0.01, ***p<0.001. 
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2d.iii.Becn1
+/-
 DCs fail to stimulate antiviral cytokine production by CD4+ T cells in 
vitro 
Innate cytokine production by DCs during antigen presentation is critical to the 
induction of Th1 adaptive immune responses, and data obtained thus far suggested that 
deficient autophagy-dependent maturation and pro-inflammatory cytokine production by 
Becn1
+/-
 DCs may result in impaired antigen presentation capacity. We first verified our 
previously published finding that blockade of autophagy in RSV-infected BMDCs leads 
to attenuated IL-17a and IFNγ production by co-cultured CD4+ T cells (230). Treatment 
of BMDCs with the autophagy inhibitor 3-methyladenine (3-MA) prior to ovalbumin 
treatment and RSV infection blocked IFNγ and RSV-associated IL-17a production by 
ovalbumin peptide-recognizing CD4+ T cells (Figure 2-5A). Similar results were 
obtained using CD11b+ pulmonary DCs, flow-sorted from lungs of naïve C57Bl/6 mice 
and co-cultured with purified CD4+ OT-II T cells (Figure 2-5B).  
As observed previously with OT-II T cells co-cultured with pulmonary CD11b+ 
DCs, RSV-infected WT BMDCs elicited greater production of IL-17a and IFNγ from co-
cultured OT-II T cells in comparison to ovalbumin treatment alone (Figure 2-5C). In 
contrast, RSV-infected Becn1
+/-
 BMDCs failed to stimulate greater production of IL-17a 
by co-cultured T cells, and elicited significantly less IFNγ production in comparison to 
both uninfected BMDCs and RSV-infected WT BMDCs (Figure 2-5C). Moreover, 
Becn1
+/-
 BMDCs infected with RSV prior to treatment with ovalbumin stimulated 
increased production of the Th2 cytokines IL-5 and IL-13 from co-cultured OT-II T cells, 
in comparison to ovalbumin treatment alone (Figure 2-5C). These results were similar to 
those obtained through co-culture of WT or Becn1
+/-
 BMDCs with CD4+ T cells purified 
from the LDLNs of RSV-infected C57Bl/6 mice, 8 days post-infection. In response to co-
culture with RSV-infected Becn1
+/-
 BMDCs, CD4+ lymph node T cells produced 
significantly greater quantities of Th2 cytokines and less IL-17a and IFNγ than T cells 
co-cultured with WT BMDCs (Figure 2-5D).  
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In order to confirm that DC elicitation of robust IL-17a and IFNγ production by 
Figure 2-5 - Elicitation of CD4+ T cell cytokine production by RSV-infected DCs is dependent on autophagy.  (A) 
WT BMDCs cultured from BALB/cJ mice were treated with saline or 5μM 3-methyladenine (3-MA), 30 minutes prior 
to the addition of 1:1 MOI RSV and 200μg/ml whole ovalbumin protein. Cells were co-cultured with purified splenic 
D011.10 CD4+ T cells, and culture supernatants tested at 48 hours by Bioplex assay. (B) CD11b+ DCs were flow-
sorted from lungs of naïve C57Bl/6 mice and co-cultured with purified splenic OT-II CD4+ T cells (C) Cytokine 
production by CD4+ OT-II T cells, co-cultured with Beclin-1+/- or wild-type BMDCs infected with RSV and treated 
with 200μg/ml whole ovalbumin protein, was measured at 48 hours by Bioplex assay. (D)Cytokine production by 
CD4+ T cells purified from LDLNs of RSV-infected C57Bl/6 mice, 8 days post-infection. Cells were co-cultured with 
RSV-infected Beclin-1+/- or WT BMDCs for 48 hours, was measured in culture supernatants by Bioplex assay.  (E,F) 
Beclin-1+/- or WT BMDCs were incubated in media or HBSS for 2 hours, placed in fresh media and treated with RSV 
and 200μg/ml whole ovalbumin protein as indicated. Production of IL-17a (E) and IFNγ (F) by co-cultured CD4+ OT-
II T cells was measured in culture supernatants at 48 hours by Bioplex assay. Data are representative of at least two 
independent experiments, with at least four replicates per group. Error bars represent SEM. *p<0.05, **p<0.01, 
***p<0.001. 
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co-cultured CD4+ T cells is indeed autophagy-dependent, we used starvation by 
incubation in HBSS as a non-viral autophagy stimulus. In agreement with our earlier 
finding that autophagy induction prior to RSV infection synergistically increases innate 
cytokine production by WT BMDCs (Figure 2-4F), CD4+ OT-II T cells co-cultured with 
either starved or RSV-infected WT BMDCs produced  greater quantities of IL-17a in 
comparison to co-cultures with BMDCs treated with ovalbumin alone (Figure 2-5E). 
Furthermore, autophagy induction prior to RSV infection in WT BMDCs augmented 
production of both IL-17a and IFNγ by co-cultured T cells in comparison to either 
treatment alone (Figure 2-5E, Figure 2-5F). In contrast, we previously found that innate 
cytokine production by starved or RSV-infected Becn1
+/-
 BMDCs was muted or 
attenuated in comparison to WT BMDCs, with no observed augmentation of cytokine 
production in response to starvation prior to infection (Figure 2-4F). Accordingly, no 
increase in production of IL-17a or IFNγ by CD4+ OT-II T cells was observed upon co-
culture with starved or RSV-infected Becn1
+/-
 BMDCs, while only a slight increase in 
IFNγ production and no change in IL-17a production was observed in co-cultures with 
Becn1
+/-
 BMDCs that were both starved and RSV-infected (Figure 2-5E, Figure 2-5F). 
Surprisingly, we found no baseline defect in the ability of Becn1
+/-
 BMDCs 
treated with ovalbumin alone to elicit cytokine production from co-cultured CD4+ OT-II 
T cells (Figure 2-5C). We also found no significant differences in the upregulation of 
MHC-II expression, costimulatory molecule expression, or cytokine production by 
Becn1
+/-
 BMDCs treated with LPS, IFNβ, or ovalbumin protein, in comparison to WT 
controls (Figure 2-6A-C). Finally, confocal microscopy revealed no evidence of 
increased autophagy in WT BMDCs treated with ovalbumin alone, suggesting that our 
ovalbumin preparation does not induce autophagy (Figure 2-6D). 
These results suggest that the autophagy-dependent production of innate 
cytokines by RSV-infected DCs is necessary for robust production of IL-17a and IFNγ by 
co-cultured CD4+ T cells, and that T cell cytokine elicitation is increased by autophagy 
induction prior to RSV infection of WT BMDCs. In contrast, while Becn1
+/-
 BMDCs 
appear to be capable of normal presentation of ovalbumin protein in the absence of an 
autophagic stimulus, the lack of increased production of IL-17a and IFNγ by CD4+ T 
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cells co-cultured with either RSV-infected or starved Becn1
+/-
 BMDCs suggests that the 
Figure 2-6 - Beclin-1+/- BMDCs mature normally in response to LPS, Type I Interferon, or ovalbumin treatment. 
(A) WT or Beclin-1+/- BMDCs were cultured 24 hours in media, or in media treated with 100ng/ml LPS or 100U/ml 
recombinant murine IFNβ. Histograms show representative cell surface expression of MHC-II, CD80, and CD86 as 
measured by flow cytometry. (B) WT or Beclin-1+/- BMDCs were cultured 24 hours in media, or in media treated with 
200μg/ml whole ovalbumin protein. Histograms show representative cell surface expression of MHC-II, CD80, and 
CD86 as measured by flow cytometry. (C) WT or Beclin-1+/- BMDCs were cultured in media, or in media treated with 
100ng/ml LPS, 100U/ml recombinant murine IFNβ, or 20ng/ml TNFα. Cytokine mRNA expression was measured by 
qPCR at 24 hours post-treatment. (D) Ovalbumin does not induce or inhibit autophagosome formation in vitro. BMDCs 
cultured from C57Bl/6 mice were treated for 2 hours with media, 1:1 MOI RSV and/or 200μg/ml ovalbumin protein as 
indicated. Cells were fixed and stained with antibodies to ATG5, followed by imaging by confocal microscopy. 
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results are due to the failure of Becn1
+/-
 BMDCs to upregulate autophagy. 
2d.iv. Adoptive transfer of RSV-infected Becn1
+/-
 DCs into wild-type mice produces 
increased lung pathology upon subsequent RSV challenge 
Data generated in the current study suggested that the primary defect leading to 
increased pathology during RSV infection in Becn1
+/- 
mice was associated with altered 
DC activation, resulting in deficient induction of antiviral cytokine production and an 
altered CD4+ T cell response.  In order to further address this mechanism, an adoptive 
transfer system was employed where WT C57Bl/6 mice were administered RSV-infected 
WT or Becn1
+/-
 BMDCs into the trachea, followed by a live RSV challenge 28 days later 
(Figure 2-7A). Since BMDCs do not propagate RSV (227, 228), the use of this model 
allows the examination of airway sensitization with an autophagy defect in DCs alone, 
and assessment of the elicited anti-viral immune response through direct RSV challenge. 
Analysis of immune cell infiltrates in enzymatically digested lungs showed that C57Bl/6 
mice administered RSV-infected Becn1
+/-
 BMDCs had increased lung infiltration of DCs 
and macrophages 8 days post-RSV challenge (Figure 2-7B). Lung histology from mice 
sacrificed 8 days post-RSV challenge revealed peribronchial inflammation within the 
lungs of all mice airway-sensitized with RSV-infected BMDCs; however this 
inflammation was much more extensive in animals given RSV-infected Becn1
+/-
 BMDCs 
(Figure 2-7C). In agreement with our findings on primary infection of Becn1
+/-
 mice, 
only RSV-infected Becn1
+/-
 BMDC recipients showed mucus plugging and granulocyte 
infiltration into the airways after challenge (Figure 2-7C). Additionally, mRNA levels of 
the mucus production-associated genes muc5ac and gob5 were significantly elevated in 
lungs of RSV-infected Becn1
+/-
 DC recipient mice in comparison to controls (Figure 
2-7D).  
In further concurrence with our findings in RSV-infected Becn1
+/-
 mice, 
examination of T cell cytokine production from restimulated LDLNs of RSV-infected 
Becn1
+/- 
BMDC recipient mice revealed increased production of IL-4, IL-5 and IL-13. 
Similarly, restimulated LDLNs produced less IL-17a in comparison to RSV-infected WT 
BMDC recipients, although IFNγ production was not significantly different (Figure 
2-7E). Finally, intracellular staining and flow cytometry revealed decreased expression of 
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Granzyme B in CD8+ T cells from lung digests of RSV-infected Becn1
+/-
 BMDC 
Figure 2-7 - Adoptive transfer of RSV-infected Beclin-1+/- dendritic cells into C57Bl/6 mice produces severe lung 
pathology upon subsequent RSV challenge. (A) DC adoptive transfer setup, with C57Bl/6 mice receiving media- or 
RSV-pulsed Beclin-1+/- or WT BMDCs i.t., followed by a live RSV challenge i.t. 28 days later. (B) Total numbers of 
lineage-positive immune cells obtained from collagenase-digested lungs of DC-sensitized mice, 8 days post-RSV 
challenge. (C)  Lung sections from DC-sensitized mice 8 days post-RSV challenge, stained with either haematoxylin 
and eosin (H&E, top panel), or haematoxylin and periodic acid schiff (H&PAS, bottom panel) stain. (D) Lung 
expression of the mucus-associated genes muc5ac and gob5 8 days post-RSV challenge was obtained using quantitative 
real-time PCR (qPCR) in comparison to naïve controls. (E) Single-cell suspensions prepared from lung-draining lymph 
nodes of DC-sensitized mice, 8 days post-RSV challenge, were restimulated in culture with RSV. Cytokine 
concentrations in culture supernatants were assayed at 48 hours using a Bioplex system. (F) Intracellular expression of 
Granzyme B by CD8a+ T cells within lung digests was assessed using flow cytometry. Data are representative of three 
independent experiments, with four to six mice per group. Error bars represent SEM. *p<0.05, **p<0.01, ***p<0.001. 
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recipients (Figure 2-7F).  These results provide additional evidence that the defect in the 
Becn1
+/-
 response to RSV resides within the DC population, leading to the observed lung 
pathology and Th2 cytokine skewed responses in fully heterozygous mice. 
2e. Discussion 
Host inflammatory responses must balance pathogen clearance with minimal 
damage to healthy tissue, and this is particularly true in the respiratory tract. In the 
current study, we provide several pieces of evidence that autophagy is critical to DC-
mediated induction of an effective antiviral adaptive immune response upon infection 
with RSV:  1) RSV-infected Becn1
+/-
 mice showed increased lung pathology 
characterized by increased mucus production and infiltration of eosinophils and DCs into 
the lungs; 2) Pulmonary DCs from RSV-infected Becn1
+/-
 mice show incomplete 
maturation in response to RSV, resulting in significantly less IFNγ and IL-17a production 
by co-cultured CD4+ T cells; 3) RSV-infected Becn1
+/-
 BMDCs fail to upregulate innate 
cytokine production upon viral and non-viral autophagy stimulus; and 4) immunization of 
WT mice through adoptive transfer of RSV-infected Becn1
+/-
 BMDC resulted in severe 
Th2-associated lung pathology upon subsequent challenge with RSV.  Investigation of 
primary airway epithelial cells indicated that there was no induction of autophagy by 
RSV infection alone and no alteration in cytokine responses observed in the epithelial 
cells from Becn1
+/-
 mice.  Thus, the altered responses appeared to be focused upon DC 
activation during RSV infection.  DCs are uniquely specialized for surveillance and rapid 
detection of invading pathogens, as well as for initiating and directing both innate and 
adaptive immune responses through antigen presentation and pro-inflammatory cytokine 
production. Histological staining of infected human lung tissue, as well as in vitro 
experiments conducted with human and mouse DCs, suggest that lung-residing 
intraepithelial DCs are capable of being directly infected with RSV (191, 201, 363). 
Infection of pulmonary DCs may be particularly important to the rapid acquisition of 
RSV antigens, as RSV infects through pH-independent cell membrane fusion and 
cytoplasmic entry (349), making autophagy mechanisms critical for rapid activation and 
antigen processing in DCs.  In agreement with recent in vivo studies implicating 
immunological autophagy in the clearance of intracellular bacteria (356), and the 
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limitation of harmful inflammation while enhancing viral clearance within infected 
neurons (278), this study identifies a role for autophagy within pulmonary DCs in 
promoting virally-induced maturation, and the priming of an effective antiviral adaptive 
immune response during RSV infection.  
Within antigen-presenting cells, autophagy modulates both pro- and anti-
inflammatory events upon activation of pattern-recognition receptors (362).  One 
mechanism whereby autophagy may promote DC maturation and innate cytokine 
production is through expedited delivery of cytoplasmic material to TLR-containing 
endosomes (297). Previous studies conducted by our laboratory support this, as 
autophagy induction within BMDCs prior to RSV infection synergistically increased 
innate cytokine production, while this effect was attenuated in BMDCs treated with 
autophagy inhibitors or cultured from TRIF- or MyD88-deficient mice (230). In 
agreement, the current findings of Th2-associated cytokine secretion, pulmonary 
eosinophilia, and mucus production in RSV-infected Becn1
+/-
 mice are consistent with 
the RSV-induced phenotype observed in mice genetically deficient in TLR3 or MyD88 
(150, 229). RSV-derived dsRNA and ssRNA, ligands specific to TLR3 and TLR7 
respectively, are likely responsible for the induction of autophagy in infected DCs, as 
synthetic ligands to TLR3 and TLR7 induce autophagosome formation in murine 
macrophages and DCs (252, 300).   Autophagy induction may therefore function as a 
positive feedback mechanism by increasing delivery of cytosolic viral components to 
endosomal TLRs, while simultaneously regulating other pro-inflammatory signals 
through inhibition of cytosolic pattern-recognition receptors (249, 318). Alternately, 
autophagy may indirectly promote TLR-dependent cytokine production by removing the 
non-structural RSV proteins NS1 and NS2 from the cytoplasm, as they disrupt TLR and 
IFN receptor signaling by decreasing intracellular expression of TRAF3 and STAT2 (34, 
365).  Further studies will be needed to address the mechanistic details of potential 
interaction of the autophagic pathway with other PRR pathways, as well as with virally-
encoded proteins during in vitro and in vivo RSV infection.  
In the current study, increased lung pathology in both RSV-infected Becn1
+/-
 mice 
and RSV-infected Becn1
+/-
 BMDC recipient mice was characterized by infiltration of 
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inflammatory DCs. Similarly, RSV-infected Becn1
+/-
 BMDCs failed to mature upon RSV 
infection in vitro, and subsequently promoted increased Th2 cytokine synthesis from co-
cultured CD4+ T cells. Inflammatory DCs, which are phenotypically similar to BMDCs 
(366) and are derived in vivo from blood monocytes (367, 368), are recruited in large 
numbers to the respiratory tract in both infected humans and mice (188, 201), and have 
been shown to drive Th2-associated lung pathology in mice during infection with the 
paramyxovirus Sendai virus (369) and in a mouse model of allergic asthma (366). 
Previous studies also noted that addition of BMDCs to the respiratory tract at the time of 
RSV infection increased lung pathology (229), while blockade of inflammatory DC 
emigration into lungs by genetic CCR6 deficiency or CCL20 neutralization increased 
viral clearance and reduced lung pathology upon RSV infection (226). In agreement, 
RSV-infected Becn1
+/-
 mice showed elevated production of CCL20 and increased lung 
infiltration by inflammatory DCs. Furthermore, transfer of RSV-infected Becn1
+/-
 
BMDCs into WT host mice induced greater Th2 cytokine production and lung pathology 
upon subsequent challenge with RSV, ultimately suggesting that impaired maturation in 
inflammatory DCs may enhance Th2-associated pathology. In contrast, we found that 
while Becn1
+/-
 CD103+ and CD11b+ lung DCs stimulated significantly less IFNγ and IL-
17a production from co-cultured OT-II T cells upon infection with RSV, both WT and 
Becn1
+/-
 RSV-infected lung-derived DCs elicited substantially less Th2 cytokine 
production in comparison to RSV-infected BMDCs of either genotype. Kinetic studies of 
DC migration upon RSV infection suggest that inflammatory DCs as well as lung-
resident CD11b+ and CD103+ DCs transport viral RNA to the LDLNs (201), suggesting 
that the observed phenotype in RSV-infected Beclin
+/-
 mice is due to impaired 
autophagy-dependent maturation in both lung-resident and inflammatory DCs. The 
impaired activation and maturation of lung-resident DCs may therefore result in 
insufficient induction of an RSV-specific Th1 response, enabling Th2 cytokine-driven 
pathology in its absence.  The role of autophagy in various lung DC subsets and the 
associated contribution to CD4+ T cell activation during RSV infection remains to be 
explored. 
While potential non-autophagic functions of Becn1 in DC activation and function 
cannot be ruled out at the present time, this study provides supportive evidence for the 
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critical role of autophagy in DCs in the induction of antiviral CD4+ T cell responses to 
RSV infection. This is supported not only by the current findings in Becn1
+/-
 mice and in 
vitro studies of DC function, but more importantly through adoptive transfer of RSV-
infected Becn1
+/-
 DCs into fully wild-type mice. The recapitulation of increased Th2 
cytokine production and occlusion of the airways with mucus and cellular debris in  
Becn1
+/-
 BMDC recipients emphasizes that impaired autophagy within RSV-infected 
DCs alone is sufficient to induce much of the lung pathology observed in fully 
heterozygous mice. However, additional studies utilizing other models of autophagy 
deficiency will be necessary to further elucidate the exact mechanism by which 
autophagy in DCs contributes to host defense against RSV. 
Genome-wide association studies recently identified autophagy gene 
polymorphisms associated with increased susceptibility to disease, including tuberculosis 
infection in human populations (370), as well as the development of Crohns disease 
(371). Interestingly, one recent study showed that viral infection interacting with 
underlying genetic susceptibility produces autoimmune illness in mice harboring the 
human ATG16L1 variant associated with increased Crohns disease risk (372). As severe 
RSV and other viral infections in infancy is associated with an increased risk of 
developing atopic asthma later in life (60, 62), it seems plausible that polymorphisms in 
autophagy genes may lead to pathological responses to respiratory viral infection early in 
life and the establishment of a Th2-skewed lung environment.  Future studies addressing 
the importance of autophagy in different DC subsets may provide valuable information 
regarding respiratory viral infections and novel vaccination strategies. 
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Chapter 3 -  Deficiency of autophagy protein Map1-LC3b 
mediates IL-17-dependent lung pathology during respiratory 
viral infection via ER stress-associated IL-1 
3a. Abstract 
While recent studies suggest that IL-1β production is modulated by 
macroautophagy or sensors of ER stress upon pro-inflammatory insult, autophagy and IL-
1β production during viral infection has not been fully investigated. This was addressed 
using respiratory syncytial virus (RSV), which is associated with lung immunopathology, 
IL-1, and IL-17a secretion in severely infected patients. Mice deficient in the autophagy-
associated protein Map1-LC3b (LC3b
-/-
) developed increased IL-17a-dependent lung 
pathology upon infection. RSV-infected LC3b
-/-
 DCs fail to upregulate autophagosome 
formation, secrete IL-1β and IL-6, and elicit IL-17a production from CD4+ T cells. Bone 
marrow chimeras revealed both structural and hematopoietic LC3b deficiency contribute 
to the development of IL-17a-dependent lung pathology in vivo. Further investigation 
revealed airway epithelium as the primary source of IL-1β during infection, while 
inhibition of the ER-stress sensor IRE-1 in primary airway epithelial cells reduced IL-1β 
production identifying a primary ER stress pathway. Finally, blockade of IL-1 receptor 
signaling in RSV-infected LC3b
-/-
 mice abolished IL-17a-dependent lung pathology. 
These findings provide novel mechanistic insight into the contribution of autophagy- and 
ER stress-dependent cytokine production that initiate and maintain aberrant Th17 
responses, while identifying IL-1 as a potential therapeutic target in the treatment of 
severe respiratory viral infections. 
3b. Introduction 
Human respiratory syncytial virus (RSV) remains the leading cause of infant 
hospitalization in the United States (373, 346), and is responsible for considerable 
morbidity among infants, the elderly, and individuals with chronic respiratory illnesses 
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worldwide (5, 55, 56). Hospitalization with RSV as an infant is also highly correlated 
with the development of recurrent wheezing in childhood, suggesting lasting immune 
environment alteration in the lung post-infection (62). The severity of lower-respiratory 
tract RSV infection in otherwise healthy individuals is largely driven by an over-
exuberant immune response to the virus, and is characterized by bronchiolitis, epithelial 
cell sloughing, mucus hyper-secretion, and infiltration of neutrophils into the airways (18, 
37). Elevated levels of the pro-inflammatory cytokines IL-1, IL-6 and IL-17a have 
recently been noted in respiratory aspirate samples from patients hospitalized with severe 
RSV infections (51, 374, 375), while experimental evidence suggests that IL-17a 
production drives mucus hypersecretion, neutrophil infiltration, and the suppression of 
CD8+ T cell responses in the context of RSV infection (374, 376, 377). The mechanisms 
by which Th17 immune responses to RSV are initiated and maintained remains poorly 
understood. 
Within the lung environment, resident dendritic cells (DCs) detect invading 
pathogens and mediate both innate and adaptive immune responses through cytokine 
secretion and antigen presentation to T cells.  Classical induction of IL-17a production by 
murine CD4+ T cells requires expression of the innate cytokines IL-6 and TGFβ by 
antigen-presenting cells (APCs), while IL-23 is required for the expansion and survival of 
Th17 cells (378, 379). In contrast, the induction of IL-17a secretion by human CD4+ T 
cells requires IL-1 and IL-6 but not TGFβ (380), while IL-1 receptor signaling is required 
for the production of IL-17a by both human and mouse CD4+ T cells (381). The 
production of IL-23 by DCs in response to TLR ligands is further driven by IL-1β (382), 
suggesting a critical role for IL-1 in the maintenance of Th17 responses.  
The IL-1 family proteins IL-1β and IL-18 are synthesized upon TLR activation in 
an inactive precursor state, and regulated via post-translational cleavage by assembled 
inflammasome complexes such as AIM2 and NLRP3 (233). The secretion of IL-1β and 
IL-18 by DCs and macrophages upon TLR activation is also negatively regulated by 
macroautophagy (autophagy), a homeostatic mechanism by which cytosolic constituents 
are enveloped in a double-walled membrane and delivered to lysosomes for degradation. 
Pro-IL-1β and pro-IL-18 are rapidly sequestered within autophagosomes upon the 
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induction of autophagy (320), while ubiquitinated inflammasomes are bound by 
sequestosome-1/p62 and selectively targeted to nascent autophagosomes through p62 
binding to membrane-bound Map-1LC3b (LC3b)(249). It was recently reported that RSV 
infection activates the NLRP3 inflammasome and induces IL-1β secretion from human 
bronchial epithelial cells (383), as well as murine macrophages and epithelial cells (131). 
Our laboratory has found evidence supporting a critical role for autophagy in DCs by 
promoting activation, cytokine secretion, and antigen presentation upon RSV infection in 
vitro (230), while autophagy deficiency in DCs enhances RSV-induced pathology in vivo 
(228). However, the potential modulatory role of autophagy in controlling excessive 
inflammasome activation and IL-1β secretion during RSV infection has yet to be 
examined. 
Since RSV infects via a membrane fusion event that allows direct entry of its 
genetic material into the cytoplasm, activation of critical innate TLR responses rely on 
autophagy to transport viral PAMPs and promote appropriate anti-viral responses (230).  
To investigate the potential role of autophagy in mitigating RSV-induced lung pathology 
in vivo, mice deficient in the critical autophagy protein LC3b (LC3b
-/-
) were used. These 
mice have been previously reported to express greater NLRP3 inflammasome activation, 
IL-1β secretion, and increased susceptibility to experimental sepsis (235). Our results 
demonstrate that LC3b is critical to the regulation of Th17-induced lung pathology during 
RSV infection, as LC3b
-/-
 mice show greater mucus hypersecretion, lung neutrophil 
infiltration, and IL-17a production, which was ameliorated by IL-17a neutralization. 
These disease-associated pathologies were associated with increased IL-1β and IL-6 
production in the LC3b deficient mice during RSV infection that were related to ER 
stress responses based upon specific pathway blockade.  Importantly, the blockade of IL-
1 receptor signaling in vivo substantially reduced IL-17a secretion and immunopathology 
in the lungs of LC3b
-/-
 mice. These findings suggest that neutralization of IL-1 may 
represent a potential therapeutic approach to alleviating severe RSV-induced responses. 
3c. Materials and methods 
Mice 
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Female C57Bl/6J and B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II) mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME). B6;129P2-Map1lc3b
tm1Mrab
/J were obtained 
from The Jackson Laboratory and repeatedly backcrossed to C57Bl/6J mice to produce 
WT or LC3b-deficient (LC3b
-/-) mice of ≥98% C57Bl/6 background. All in vivo 
experiments utilized age- and sex-matched WT or LC3b
-/-
 littermates.  
Bone marrow chimeras were created by irradiating WT or LC3b
-/-
 littermates at 900rad, 
followed by tail-vein injection of 2 x 10
6
 whole bone marrow cells of the genotype 
indicated. Chimeras were allowed to reconstitute for 8 weeks prior to RSV infection. All 
work involving animals was conducted in accordance with University of Michigan 
Committee on Use and Care of Animals policy. 
Respiratory Syncytial Virus 
All experiments utilized antigenic subgroup A, Line 19 strain RSV, originally isolated 
from a sick infant in the University of Michigan Health System. Viral stocks were 
maintained in Hep-2 cell cultures.  
Dendritic Cell Isolation and Culture  
Bone marrow-derived dendritic cells (BMDCs) were cultured in complete media as 
previously described (228), from whole bone marrow in the presence of 20ng/ml GM-
CSF (R&D Systems, Minneapolis, MN). Lung-resident CD11b+ and CD103+ DCs were 
isolated by enzymatic digestion of lungs of naïve WT or LC3b
-/-
 mice as previously 
described (228). Briefly, minced lung tissue was incubated with 200μg/ml Liberase TM 
(Roche Applied Science, Indianapolis, IN) and 200U/ml DNase I (Sigma-Aldrich), drawn 
through an 18-gauge needle, and filtered through 40μm mesh. Cells were positively 
selected for CD11c expression using anti-mouse CD11c microbeads and magnetic 
column separation (Miltenyi Biotec, Auburn CA), followed by staining with PE-labeled 
anti-CD11b and allophycocyanin-labeled anti-CD103 Abs (eBioscience, San Diego, CA). 
Cells were sorted on an iCyt Synergy 3200 fluorescence-activated cell sorter 
(Champaign, IL), followed by overnight culture in complete media.  
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For DC-T cell co-culture experiments, RSV-responsive CD4+ T cells were obtained from 
mediastinal lymph nodes of RSV-infected C57Bl/6J mice, 8 days post-infection. CD4+ 
OT-II T cells were isolated from minced spleens of OT-II transgenic mice.  Cells were 
purified using a magnetic column negative-selection protocol, yielding untouched CD4+ 
T cells (Miltenyi Biotec). CD4+ T cells were added to culture at a 10:1 ratio to DCs. For 
RSV-reactive T cell co-cultures, DCs were infected with RSV at an MOI of 1, 2 hours 
prior to the addition of T cells. For OT-II T cell co-cultures, DCs were treated with 
200μg/ml whole ovalbumin protein, or concurrently treated with ovalbumin and 1:1 MOI 
of RSV, for 2 hours prior to the addition of T cells. Culture supernatants were harvested 
at 48 hours and analyzed using a custom BioRad Bioplex PRO kit on a BioRad Bioplex 
200 system, according to manufacturer instructions (BioRad).  
Airway Epithelial Cell culture 
Airway epithelial cell cultures were prepared from lungs of naïve mice by digestion in 
Dispase (BD Biosciences), followed by filtration through 25μm nylon mesh. Immune 
cells were depleted using biotinylated anti-CD45 antibodies and streptavidin-conjugated 
Dynabeads (Thermo Fisher Scientific). Cells were plated on 10cm tissue culture dishes 
and adherence-purified in DMEM-based complete media, followed by 4 day culture in 
fibronectin-coated wells.  
Reagents 
Recombinant mouse IL-1Ra was obtained from R&D systems. Neutralizing antibodies to 
mouse IL-17a were generated and purified in-house, as described previously (374). The 
ER stress inhibitors 3,5-dibromosalicylaldehyde and 4-phenylbutyrate were purchased 
from Santa Cruz Biotechnology. 
Quantitative PCR 
Total RNA was isolated from cell cultures and lung tissue using TRIzol reagent, 
according to manufacturer’s instructions (Invitrogen). RNA was reverse-transcribed, and 
cytokine gene expression was assessed using TaqMan Gene Expression Assay 
primer/probe sets on an ABI Prism 7500 Sequence Detection System (Applied 
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Biosystems, Foster City, CA). Custom primers were used to assess transcription levels of 
muc5ac, gob5, RSV-G and RSV-F, as previously described (155). Fold change expression 
was calculated from gene expression values normalized to GAPDH, relative to the 
indicated control group. 
Flow Cytometry 
Cells were isolated from the right lungs and mediastinal LNs by digestion in 200μg/ml 
Liberase TM (Roche Applied Science, Indianapolis, IN) and 200U/ml DNase I (Sigma-
Aldrich). Cells were stained with Live/Dead Fixable Yellow (Invitrogen), followed by 
fluorescent antibodies as indicated. Analysis was performed using FlowJo software 
(TreeStar, Ashland OR).  
Immunofluorescence and Confocal Microscopy 
BMDCs and AECs were cultured as described above, and plated in Labtek chamber 
slides (Thermo Fisher Scientific). After indicated treatment, cells were fixed in 4% 
paraformaldehyde, followed by blocking in DPBS containing 5% normal goat serum and 
0.1% Tween-20. Cells were stained with DyLight 550-conjugated anti-ATG5 antibodies 
(Novus Biologicals, Littleton, CO), or rabbit anti-Caspase-1 p10 (Santa Cruz 
Biotechnologies) followed by Alexa Fluor 488-conjugated goat anti-rabbit antibodies 
(Jackson ImunoResearch, West Grove, PA). Slides were mounted in ProLong Gold 
antifade reagent plus DAPI, and imaged using 40x oil immersion objective on a Nikon 
A1 Confocal Microscope System using NIS Elements software (Nikon Instruments). 
Maximum intensity projection images were generated using ImageJ software (National 
Institutes of Health). 
For fluorescent immunohistochemistry. formalin-fixed paraffin-embedded lung sections 
were de-parrafinized, rehydrated, and incubated overnight in antigen retrieval buffer 
(0.01M Citric acid, pH 6.0). Slices were blocked in DPBS + 2% normal goat serum, 
followed by incubation with rabbit anti-mouse IL-1β (Novus Biologicals, Littleton, CO) 
and biotinylated anti-E-cadherin (BD Biosciences). After washing in blocking buffer, 
slices were incubated with anti-rabbit Alexa Fluor 568 and streptavidin-conjugated Alexa 
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Fluor 488 (BD Biosciences). Images were taken using a 40x objective on an Olympus 
BX43 fluorescent microscope. 
Statistics 
Data were analyzed and graphed using GraphPad Prism software. Statistical significance 
was determined by one-way ANOVA and Bonferroni post-test to obtain p values. 
3d. Results 
3d.i. LC3b
-/-
 mice develop increased IL-17a-dependent lung pathology upon RSV 
infection 
Upon intratracheal infection with RSV, LC3b
-/-
 mice developed increased lung 
pathology in comparison to RSV-infected WT littermates, with increased 
periarteriolar/peribronchiolar immune cell infiltration visible by haematoxylin and eosin 
(H & E) histological staining at 8 days post-infection (Figure 3-1A). Additionally, greater 
periodic acid-schiff (PAS)-positive mucus staining was visible along the apical epithelial 
surface of the major airways of RSV-infected LC3b
-/-
 mice (Figure 3-1A), while mRNA 
transcripts for the mucus-associated genes muc5ac and gob5 were elevated in the lungs of 
RSV-infected LC3b
-/-
 mice (Figure 3-1B). In order to assess lung viral replication, qPCR 
for mRNA transcripts encoding the RSV-G and –F proteins was performed on whole 
lung homogenates. This revealed increased viral transcripts in the lungs of infected LC3b
-
/-
 mice, which suggests decreased viral clearance relative to WT littermates (Figure 
3-1C). Analysis of immune cells in collagenase-digested lung tissue revealed 
significantly higher numbers of neutrophils and eosinophils in the lungs of RSV-infected 
LC3b
-/-
 mice (Figure 3-1D), while fewer Granzyme-B positive CD8a+ T cells were 
present in comparison to WT littermates (Figure 3-1E).  
Experimental evidence has shown a causative role for T cell-associated cytokines, 
most recently IL-17a, in the development of severe lung pathology during RSV infection 
(374). Therefore, lung expression of IL-17a and IFNγ was examined and results 
demonstrated that the expression of IL-17a mRNA was elevated in the lungs of RSV-
infected LC3b
-/-
 mice (Figure 3-1F). Conversely, mRNA expression of IFNγ was 
significantly lower in comparison to WT littermate controls (Figure 3-1F). In addition, 
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mediastinal lymph node (MedLN) cells prepared from RSV-infected LC3b
-/-
 mice 
restimulated ex vivo with RSV secreted greater quantities of IL-17a (Figure 3-1G). As IL-
1, IL-6, and TGFβ are required for the induction of mucosal Th17 responses in mice 
(379, 381), lung mRNA expression was examined and IL-1β and IL-6 mRNA were found 
to be elevated in the lungs of LC3b
-/-
 mice (Figure 3-1H), while TGFβ expression did not 
differ in comparison to RSV-infected WT littermates (data not shown).  
Previous studies conducted by our laboratory found that IL-17a production 
contributes to lung inflammation, excessive mucus production, and the suppression of 
IFNγ production during RSV infection (151, 374). To assess whether the increased lung 
pathology in RSV-infected LC3b
-/-
 mice was IL-17a-dependent, LC3b
-/-
 mice were 
Figure 3-1 - LC3b-/- mice develop increased lung pathology upon RSV infection. A) Lung sections of WT or LC3b-/- 
mice, 8 days post-infection (DPI) with RSV, were stained with either haematoxylin and eosin (H & E, upper panels) or 
periodic acid schiff and haematoxylin (H & PAS, lower panels) to visualize mucus along airway epithelium. Scale bars 
= 500μm for upper panels, 20μm for lower panels. B) Lung mRNA expression of muc5ac and gob5 at 8 DPI was 
obtained by qPCR, compared to naïve controls. C) mRNA transcripts from lungs, encoding RSV-G and –F proteins, 
were measured by qPCR and normalized to values of WT RSV-infected lung samples. D) Neutrophils and eosinophils 
in right lungs of WT and LC3b-/- mice at 8 DPI were quantified by flow cytometry, following enzymatic digestion of 
lungs. Total granulocytes were gated CD11bhi CD11clo SSChi Autolo, with neutrophils gated Ly6Ghi Ly6C+ and 
eosinophils gated Ly6C+ Siglec F+. E) Granzyme-B positive (GrB+) CD3+ CD8a+ T cells in enzymatically-digested 
lung tissues were quantified by flow cytometry. F) Lung IL-17a and IFNγ values were obtained by qPCR. Fold change 
values were calculated relative to naïve control mice. G) Single-cell suspensions were prepared from mediastinal lymph 
nodes of RSV-infected WT or LC3b-/- mice at 8 DPI, followed by restimulation in culture with RSV. Cell supernatants 
were analyzed at 48 hours by Bioplex assay. H) Lung expression of IL-1β and IL-6 at 6 DPI was assessed by qPCR. 
Results are representative of three independent experiments, n≥4 mice per group. *p≤0.05, ***p≤0.001. 
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treated with neutralizing antibodies to IL-17a. In comparison to control antibody 
treatment, administration of anti-IL-17a antibodies to RSV-infected LC3b
-/-
 mice 
substantially decreased lung inflammation and mucus secretion at 8 days post-infection 
(Figure 3-2A).  In agreement, anti-IL-17a antibody treatment significantly decreased 
muc5ac expression in LC3b
-/-
 mice at 8 days post-infection (Figure 3-2B), while reducing 
lung neutrophil infiltration in comparison to control antibody administration (Figure 
3-2C). Furthermore, depletion of IL-17a in LC3b
-/-
 mice reduced lung viral mRNA to 
levels equivalent to WT controls (Figure 3-2D), and increased lung IFNγ expression 
(Figure 3-2E). These results collectively suggest that the development of increased lung 
pathology in LC3b
-/-
 mice is IL-17a-dependent. 
Figure 3-2 - Increased RSV-induced lung pathology in LC3b-/- mice is IL-17a-dependent. LC3b-/- mice were 
treated with 2.5mg non-specific control antibody, or polyclonal antibody to mouse IL-17a, immediately prior to RSV 
infection and at days 2, 4, and 6 post-infection. A) Lungs were harvested at 8 DPI, sectioned, and stained with 
haematoxylin and eosin (H & E) or haematoxylin and periodic acid schiff (H & PAS) to visualize mucus. Scale bars = 
100μm on upper panels, 20μm on lower panels. B) Lung expression of the mucin gene muc5ac was measured at 8 DPI 
by qPCR, relative to naïve controls. C) Neutrophils were quantified by flow cytometric analysis of enzymatically-
digested lungs, 8 DPI. Neutrophils were gated as indicated in Figure 3-1. D) Lung mRNA expression encoding RSV-G 
and RSV-F was assessed at 8 DPI, relative to RSV-infected WT. E) Lung IFNγ expression was measured at 8 DPI by 
qPCR. Results are representative of three independent experiments, n≥4 mice per group. *p≤0.05, **p≤0.01, 
***p≤0.001. 
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3d.ii.Altered autophagy, innate cytokine production, and CD4+ T cell cytokine elicitation 
by LC3b
-/-
 CD11b+ DCs in response to RSV infection 
Recent work identified a requirement for CD11c
high
 CD11b+ tissue-resident DCs 
in the induction of mucosal Th17 immune responses (384, 385). As pharmacological 
blockade of autophagy increases IL-23 secretion by DCs and macrophages in response to 
TLR agonists (382), the ability of LC3b
-/-
 DCs to upregulate autophagosome formation 
and secrete innate cytokines in response to RSV was investigated. Confocal microscopy 
revealed robust formation of ATG5+ autophagosomes by WT bone marrow-derived DCs 
(BMDCs) in response to RSV infection (Figure 3-3A). In contrast, LC3b
-/-
 BMDCs failed 
to increase formation of ATG5+ puncta in response to RSV (Figure 3-3A). In agreement 
with these observations, intracellular levels of the sequesteosome protein p62 decreased 
in WT BMDCs by 8 hours post-infection, while LC3b
-/-
 BMDCs continued to accumulate 
p62 over a 24 hr period (Figure 3-3B). Analysis of cytokine secretion by RSV-infected 
BMDCs revealed significantly higher production of IL-1β and IL-6 by LC3b-/- BMDCs 
(Figure 3-3C). LC3b
-/-
 BMDCs expressed less of the IL-12-specific subunit IL-12p35 and 
the IL-12/IL-23 common subunit IL-12p40 by qPCR, in comparison to WT BMDCs 
(Figure 3-3D). Conversely, the RSV-infected LC3b
-/-
 BMDCs significantly upregulated 
IL-23p19 expression in comparison to WT BMDCs (Figure 3-3D). These findings were 
confirmed using CD11c
high
 CD11b
+
 lamina propria DCs (CD11b
+
 LP DCs), flow-sorted 
from lungs of naïve WT and LC3b
-/-
 mice and infected ex vivo with RSV. LC3b
-/-
 
CD11b
+
 LP DCs secreted greater amounts of IL-1β and IL-6 upon RSV infection, while 
IL-12p35 and IL-12p40 mRNA expression were significantly reduced in comparison to 
WT controls (Figure 3-3E, F).   
In order to assess whether
 
LC3b
-/-
 DCs preferentially elicit increased IL-17a 
secretion from CD4+ T cells, RSV-infected BMDCs were co-cultured with purified 
CD4+ T cells derived from MedLNs of RSV-infected WT mice. CD4+ MedLN T cells 
secreted significantly greater quantities of IL-17a in co-culture with RSV-infected LC3b
-
/-
 BMDCs, in comparison to T cells co-cultured with WT BMDCs (Figure 3-3G). To 
further investigate the elicitation of CD4+ T cell IL-17a secretion as a consequence of 
autophagy deficiency, purified CD4+ splenic OT-II T cells were co-cultured with 
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BMDCs pulsed with ovalbumin protein in the presence or absence of RSV, as ovalbumin 
treatment alone does not induce autophagy. While co-cultures in which WT and LC3b
-/-
 
Figure 3-3 - Altered autophagic flux, innate cytokine production, and elicitation of CD4+ T cell IL-17a 
production by LC3b-/- DCs in response to RSV. Bone marrow-derived DCs (BMDCs) were cultured from naïve WT 
or LC3b-/- mice, then infected for 4 hours with RSV. Cells were fixed, stained with DAPI and fluorescent antibody to 
ATG5, and imaged by confocal microscopy. Scale bars = 10μm. B) BMDCs were cultured and infected with RSV, 
followed by harvest at 4, 8, 12, and 24 hours post-infection. Whole cell lysates were run on SDS-PAGE gels, followed 
by membrane transfer and immunoblot for p62 or β-actin as indicated. C) BMDCs were infected with 1:1 MOI RSV 
and cell supernatants analyzed at 48 hours post-infection by Bioplex assay. D) BMDCs were infected as above, 
harvested at 24 hours post-infection, and gene expression analyzed by qPCR. E) Lung-resident CD11chi Autolo CD11b+ 
lamina propria DCs (CD11b+ LP DCs) were flow-sorted from enzymatically-digested lungs of naïve WT and LC3b-/- 
mice. Cells were infected ex vivo with 1:1 MOI RSV, and cell supernatants harvested at 48 hours post-infection by 
Bioplex assay. F) Lung-resident CD11b+ LP DCs were isolated and infected with RSV as previously described, 
followed by gene expression analysis by qPCR at 24 hours post-infection. G) CD4+ T cells were purified from 
mediastinal lymph nodes of WT RSV-infected mice, 8 days post-infection. Cells were plated at a 10:1 ratio over WT or 
LC3b-/- BMDCs, infected 2 hours previously with 1:1 MOI RSV. Culture supernatant IL-17a concentrations were 
measured at 48 hours by Bioplex assay. WT or LC3b-/- BMDCs (H) or CD11b+ LP DCs (I) were pulsed with whole 
ovalbumin protein in the presence or absence of 1:1 MOI RSV, followed by the addition of 10:1 purified splenic OT-II 
CD4+ T cells. Culture supernatant IL-17a concentrations were measured at 48 hours by Bioplex assay. All results are 
representative of at least three independent experiments. *p≤0.05, **p≤0.01, ***p≤0.001. 
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DCs were treated with ovalbumin alone produced similar quantities of IL-17a, cultures in 
which LC3b
-/-
 DCs were concurrently infected with RSV elicited significantly greater IL-
17a production from the CD4+ OT-II T cells (Figure 3-3H). These findings were 
confirmed using CD11b
+
 LP DCs isolated from naïve WT and LC3b
-/-
 mice, with RSV-
infected and ovalbumin-pulsed LC3b
-/-
 CD11b
+
 LP DCs eliciting significantly higher 
quantities of IL-17a from co-cultured OT-II T cells (Figure 3-3I). These results support 
impaired autophagy and altered innate cytokine production by LC3b
-/-
 DCs as primary 
mechanisms in the initiation of Th17-skewed CD4+ T cell responses to RSV infection. 
3d.iii. Non-Immune cell deficiency in LC3b augments Th17-associated RSV pathology 
through increased IL-1 secretion by airway epithelial cells 
Results thus far indicated that LC3b
-/-
 CD11b+ DCs elicit increased IL-17a 
production from CD4+ T cells in response to RSV.  As LC3b expression in epithelial 
cells is an important modulator of lung pathology upon exposure to cigarette smoke (386) 
or hyperoxia (387),  bone marrow chimeric mice were created to assess relative 
contributions of structural and hematopoietic cells to observed RSV-induced lung 
pathology.  Histological examination of lung tissue 8 days post-infection revealed that 
WT and LC3b
-/-
 mice reconstituted with LC3b
-/-
 bone marrow experienced comparable 
significant increases in lung inflammation, infiltration of neutrophils, and IL-17a 
expression in comparison to fully WT chimeric animals (Figure 3-4A-C). These findings 
support the in vitro findings described above, confirming that hematopoietic LC3b 
deficiency is sufficient to induce increased IL-17 production and neutrophil infiltration in 
response to RSV in vivo. 
Unexpectedly, reconstitution of LC3b
-/-
 mice with WT bone marrow produced an 
augmented inflammatory response, as significantly higher numbers of neutrophils were 
found in the lungs in comparison to all other treatment groups (Figure 3-4B).  These 
PMN accumulation data correlated well with qPCR analysis that revealed augmented 
expression of IL-17a in lung tissues (Figure 3-4C) and reduced expression of IFNγ 
(Figure 3-4D), with the WT to LC3b
-/-
 chimera having the most significant effect. 
Elevated IL-17a secretion was similarly observed in MedLN cultures stimulated ex vivo 
with RSV (Figure 3-4E). Finally, investigation of innate cytokine expression in the lungs 
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of chimeric mice revealed increased IL-6 and IL-1β mRNA transcript in RSV-infected 
LC3b
-/-
 chimeric mice, independent of WT or LC3b
-/-
 bone marrow reconstitution (Figure 
3-4F,G), implicating structural cells as the primary source of these cytokines in the lungs.  
These findings collectively suggest that while LC3b
-/-
 bone marrow is sufficient for the 
development of increased Th17-dependent lung pathology in response to RSV, LC3b
-/-
 
Figure 3-4 - Both structural and hematopoietic LC3b deficiency contribute to increased lung pathology during 
RSV infection. WT and LC3b-/- mice were lethally irradiated and reconstituted with whole bone marrow from WT or 
LC3b-/- donors, as indicated. Chimeric mice were infected with RSV and sacrificed 8 days post-infection. A) Lung 
sections were stained with haematoxylin and eosin (H & E) to visualize inflammation. Scale bars = 100μm. B) 
Neutrophils were quantified from enzymatically-digested lungs by flow cytometry. Neutrophils were gated as indicated 
in Figure 3-1. Lung mRNA expression of IL-17a (C) and IFNγ (D) was measured by qPCR, relative to naïve controls. 
E) Single-cell suspensions were prepared from mediastinal lymph nodes, followed by restimulation in culture with 
RSV. Culture supernatant IL-17a production was measured at 48 hours by Bioplex assay. F,G) Lung mRNA expression 
of IL-6 and IL-1β was measured by qPCR. Results are representative of three independent experiments, n≥4 mice per 
group. *p≤0.05, **p≤0.01, ***p≤0.001. 
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lung structural cells may augment production of IL-17 in the lungs through increased 
secretion of innate cytokines. 
3d.iv.Airway Epithelial cells deficient in LC3b have enhanced inflammasome activation 
and increased cytokine production due to ER Stress 
To further examine non-hematopoietic innate cytokine production in response to 
RSV, fluorescent immunohistochemistry was used to examine IL-1β protein expression 
in lung sections of infected mice. This revealed greater staining intensity in lungs of 
RSV-infected LC3b
-/-
 mice, with the vast majority of IL-1β-positive cells co-staining for 
the epithelial marker E-Cadherin (Figure 5A). To verify these findings, primary airway 
epithelial cell (AEC) cultures were derived from lungs of naïve mice and infected with 
Figure 3-5 - Increased IL-1β and pro-inflammatory cytokine production by LC3b-/- airway epithelial cells upon 
RSV infection. A) Lung sections from WT and LC3b-/- mice, 6 days post-infection, were stained for IL-1β protein 
expression using antibodies to mouse IL-1β and E-cadherin. Sections were stained with DAPI and imaged on an 
Olympus BX43 fluorescent microscope. Scale bars = 40μm. Airway epithelial cell (AEC) cultures were prepared from 
lungs of naïve WT or LC3b-/- mice, and infected with 1:1 MOI RSV. B) IL-1β and IL-6 expression was measured at 12 
hours post-infection by qPCR, while C) IL-1β and IL-6 secretion was measured in culture supernatants at 24 hours by 
Bioplex assay. *p≤0.05, **p≤0.01, ***p≤0.001. 
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RSV in vitro.  In agreement with previous observations in lungs of LC3b
-/-
 chimeric 
mice, LC3b
-/-
 AECs upregulated IL-1β and IL-6 mRNA and secreted greater quantities of 
protein upon RSV infection, in comparison to WT cultures (Figure 5B,C).  
RSV infection is a known inducer of both ER stress and NLRP3 inflammasome 
activation in bronchial epithelial cells (345, 383). As the accumulation of damaged 
mitochondria in the absence of autophagy is a known driver of NLRP3 inflammasome 
activation (234, 235), mitochondrial sequestration was examined in RSV-infected AEC 
cultures. While mitochondrial signal colocalized with distinct ATG5-positive structures 
in WT AECs at 24 hours post-infection, LC3b-/- AECs amassed large aggregates of 
mitochondria in response to RSV infection (Figure 3-6A). In addition, prolonged ER 
stress causes mitochondrial damage and triggers NLRP3 inflammasome activation  (336). 
The expression levels of several genes activated during ER stress were therefore 
examined in RSV-infected AEC cultures. In agreement with the previous report of 
signaling through the ER stress-sensing receptor IRE-1α upon RSV infection (345), 
mRNA expression of Edem-1 and cleaved XBP-1 (XBP-1s) were significantly elevated 
in RSV-infected LC3b
-/-
 AEC cultures at 12 hours post-infection (Figure 3-6B). 
Furthermore, pre-treatment of LC3b
-/-
 AECs with the IRE-1α inhibitor 3,5-
dibromosalicylaldehyde (DBSA) reduced the secretion of IL-1β and IL-6 to levels 
comparable to WT AECs (Figure 3-6C,D). Finally, in order to assess the contribution of 
ER stress to inflammasome activation during RSV infection, expression of the active p10 
subunit of caspase-1 was measured in primary AEC cultures infected with RSV. 
Confocal imaging and fluorescence quantification of caspase-1 p10 antibody staining 
revealed increased signal in LC3b
-/-
 AECs 12 hours post-treatment with RSV, in 
comparison to WT control cultures (Figure 3-6E). Pre-treatment of LC3b
-/-
 AECs with 
DBSA abolished this difference (Figure 3-6E). Collectively, these results suggest that 
elevated RSV-induced production of IL-1β and IL-6 by the LC3b-/- airway epithelium is 
due to increased inflammasome activation and ER stress, and may have a critical role in 
shaping the ongoing immune response during RSV infection. 
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3d.v. Blockade of IL-1 receptor signaling ameliorates IL-17a-associated pathology in 
LC3b
-/-
 mice in vivo 
Figure 3-6 – Mitochondrial accumulation and IRE-1α-dependent increase of IL-1β production in RSV-infected LC3b-/- 
AECs. A) AECs were pulsed with Mitotracker 30 minutes prior to infection with 1:1 MOI RSV. Cells were stained at 
24 hours post-infection with anti-ATG5 antibodies and DAPI, followed by imaging on a Nikon A1 confocal 
microscope. Scale bar = 10μm. B) mRNA transcripts of IRE-1α-associated genes Edem-1 and spliced XBP-1 were 
assessed in AECs at 12 hours post-infection by qPCR. (C,D) AECs were treated with the IRE-1α inhibitor 3,5-
dibromosalicylaldehyde (DBSA) at 40μM 30 minutes prior to 1:1 MOI RSV. Concentrations of IL-1β (C) and IL-6 (D) 
were measured in cell supernatants at 24 hours post-infection by Bioplex assay. E) AECs were infected for 12 hours 
with 1:1 MOI RSV, then fixed and stained with antibodies to the Caspase-1 p10 subunit and DAPI. Cells were imaged 
on a Nikon A1 confocal microscope. Fluorescence intensity per cell was measured and quantified using maximum 
intensity projections, using ImageJ software. Scale bars = 30μm. Results are representative of at least two independent 
experiments. *p≤0.05, **p≤0.01, ***p≤0.001. 
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In order to assess whether excessive IL-1 production was driving the development 
of the elevated Th17 response in LC3b
-/-
 mice, murine IL-1 receptor antagonist (IL-1Ra) 
was administered immediately prior to and during the course of RSV infection.  
Strikingly, LC3b
-/-
 mice treated with IL-1Ra during RSV infection showed substantially 
reduced peribronchial inflammation in comparison to LC3b
-/-
 saline treatment controls 
(Figure 3-7A). Treatment with IL-1Ra decreased PAS-positive mucus in the airways of 
RSV-infected LC3b
-/-
 mice (Figure 3-7A, lower panels), which was verified through 
significantly reduced mRNA expression of muc5ac in lung homogenates (Figure 3-7B). 
Quantification of lung neutrophils by flow cytometry revealed decreased neutrophil 
infiltration in IL-1Ra-treated LC3b
-/-
 mice, in comparison to saline-treated controls 
(Figure 3-7C). Examination of cytokine production in lungs by qPCR revealed 
Figure 3-7 - Increased IL-17a-dependent lung pathology in RSV-infected LC3b-/- mice requires IL-1 receptor 
signaling. LC3b-/- mice were injected I.P. with 25mg/kg mouse IL-1 receptor antagonist (IL-1Ra) immediately prior to 
RSV infection, then treated once daily until sacrificed at 8 days post-infection. A) Lung sections were stained with 
haematoxylin and eosin (H & E) or haematoxylin and periodic acid schiff (H & PAS) to visualize mucus. Scale bars = 
100μm on upper panels, 20μm on lower panels. B) Lung expression of muc5ac was measured by qPCR. C) Neutrophils 
were quantified in enzymatically-digested lung tissue by flow cytometry, using cell surface antigens detailed in Figure 
3-1D) Expression of IL-17a and IFNγ were measured in lungs by qPCR. E) Single-cell suspensions prepared from 
mediastinal lymph nodes were restimulated in culture with RSV. IL-17a concentrations in supernatants were measured 
at 48 hours post-infection by Bioplex assay. Results are representative of two independent experiments, n≥5 mice per 
group. *p≤0.05, **p≤0.01, ***p≤0.001. 
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significantly reduced IL-17a expression in IL-1Ra-treated LC3b
-/-
 mice, with a 
concomitant increase in IFNγ production in response to RSV infection (Figure 3-7D). 
Finally, IL-17a secretion by MedLN cells restimulated ex vivo was significantly reduced 
in cultures from LC3b
-/-
 mice who received IL-1Ra treatment (Figure 3-7E). These 
results ultimately suggest that elevated IL-17a production and associated lung pathology 
in RSV-infected LC3b
-/-
 mice are driven by IL-1 receptor signaling. 
3e. Discussion 
In this manuscript, we provide evidence for the importance of the autophagy 
protein LC3b in both innate cytokine production and the induction of adaptive immune 
responses to RSV. Mice deficient in LC3b developed greater IL-17a-dependent lung 
pathology upon RSV infection, characterized by neutrophil infiltration, mucus 
hypersecretion, and decreased viral clearance in comparison to WT littermates. While 
cells such as γδ T cells and NK cells are capable of producing IL-17a, previous 
observations suggest that CD4+ T cells are the primary source of IL-17a at 8 days post-
RSV infection (374). In agreement with previous work showing a requirement for 
autophagy in innate cytokine production by DCs (230, 382), RSV-infected LC3b
-/-
 DCs 
produced IL-1β, IL-6, and IL-23 at the expense of IL-12 and preferentially elicited IL-
17a production from CD4+ T cells (Figure 3-8A). In further support of DC-mediated 
induction of deleterious Th17 responses, hematopoietic LC3b deficiency was sufficient 
for the development of elevated lung pathology in response to RSV. Unexpectedly, 
structural deficiency in LC3b augmented the development of IL-17-dependent lung 
pathology, as infected LC3b
-/-
 airway epithelial cells secreted greater amounts of IL-1β in 
a manner dependent on elevated IRE-1α signaling (Figure 3-8B). Finally, treatment of 
LC3b
-/-
 mice with IL-1Ra attenuated IL-17a production and associated lung pathology in 
response to RSV, implicating enhanced IL-1 receptor signaling in the development of IL-
17-driven lung pathology. The identification of these innate pathways may lead to new 
strategies to alleviate pathophysiologic changes during RSV infection that lessen severity 
and subsequent long term sequelae of pulmonary damage associated with RSV. 
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Since the discovery of Th17 cell lineage, aberrant or excessive Th17 immune 
responses have been found to enhance pathology in the context of immune-mediated 
disorders such as rheumatoid arthritis (388) and allergic asthma (389), as well as during 
viral infection (390).  Studies of severe RSV infection suggest that a Th17-skewed 
response contributes to lung pathology in at least a subset of patients, as elevated IL-17a 
expression has been reported in tracheal aspirates of infants hospitalized with RSV (374, 
391). In addition, lung expression of IL-6 and IL-1 are correlated with severity of disease 
in both infants and adults infected with RSV (51, 392). IL-17a may drive lung pathology 
by inducing mucus gene expression (393) and potentiating IL-8 production in RSV-
infected bronchial epithelial cells, thereby augmenting lung neutrophil recruitment (391). 
Figure 3-8 - Proposed mechanisms of the induction and maintenance of CD4+ T cell responses to RSV in wild-
type or LC3b-/- mice. A) Upon detection of RSV by WT lung DCs, rapid induction of autophagy facilitates IL-12 
production, ultimately promoting the development of a Th1 response by RSV-reactive CD4+ T cells. In contrast, LC3b-
/- DCs fail to upregulate autophagy upon encountering RSV, resulting in the production of IL-1β, IL-6, and IL-23. This 
cytokine environment skews RSV-reactive CD4+ T cells toward a Th17 phenotype. B) RSV-infected lung epithelial 
cells upregulate signaling through the ER stress sensor IRE-1, potentially triggering LC3b-dependent autophagosomal 
degradation of ER and damaged mitochondria, thereby alleviating RSV-induced stress and minimizing IL-1 
production. In the absence of LC3b expression, RSV-infected epithelial cells experience increased IRE-1 signaling 
owing to unchecked ER stress, resulting in caspase-1 cleavage and mature IL-1 production. This enhanced IL-1 
secretion stimulates further IL-17a production from CD4+ effector T cells through IL-1 receptor signaling. 
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This is supported by previous findings in our laboratory in animal models of RSV 
infection, as administration of neutralizing antibodies to IL-17a attenuated lung mucus 
production and neutrophil infiltration (151, 374). In the present studies treatment of 
LC3b
-/-
 mice with anti-IL-17a antibodies during RSV infection significantly decreased 
lung neutrophil infiltration and mucus hypersecretion, while also elevating lung IFNγ 
expression. Moreover, in vivo blockade of IL-1 receptor signaling through IL-1Ra 
treatment mitigated lung production of IL-6 and IL-17a in RSV-infected LC3b
-/-
 mice, 
resulting in reduced lung pathology. These findings not only provide further evidence in 
support of the critical role of LC3-dependent autophagy secretion during infectious insult 
(235), but also provide novel evidence supporting the role of autophagy in counteracting 
deleterious Th17 responses to RSV through blocking inflammasome-mediated production 
of IL-1β. 
The production of IL-23 by DCs and macrophages is also indirectly regulated by 
autophagy, through autophagy-mediated inhibition of IL-1 secretion (382).  The 
alteration of autophagy reduces the ability to shuttle RSV RNA to endosomic TLR 
pathways, which have been shown to be associated with regulation of IL-23 and IL-17a 
(151). Accordingly, we found that RSV-infected LC3b
-/-
 DCs that failed to upregulate 
autophagosome formation secreted more IL-1β, IL-6, and IL-23, and preferentially 
induced IL-17a expression from co-cultured CD4+ T cells in comparison to WT controls. 
Experiments with chimeric mice further support a causative role for autophagy deficiency 
in DC-mediated induction of Th17 responses to RSV, as WT mice reconstituted with 
LC3b
-/-
 bone marrow developed similar lung pathology as mice fully deficient in LC3b. 
Conversely, the development of T cell-dependent lung pathology in fully LC3b
-/-
 mice 
may be dampened not only by inefficient antigen presentation by autophagy-deficient 
DCs (352, 394), but may also be due to a requirement for autophagy proteins in the 
survival and proliferation of effector T cells (395, 396). In support of this, the 
reconstitution of LC3b
-/-
 mice with WT bone marrow augmented Th17-dependent lung 
pathology above levels observed in fully LC3b
-/-
 mice. Ultimately, these results suggest 
critical roles for LC3b-dependent autophagy in both structural and hematopoietic cells in 
mitigating inflammasome activation and the development of Th17-associated lung 
pathology during RSV infection. 
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Several non-exclusive mechanisms may contribute to increased IL-1β secretion 
by LC3b
-/-
 DCs, macrophages, and airway epithelial cells in response to RSV infection. 
Our findings of increased IL-1β secretion and active caspase-1 by LC3b-/- AECs concurs 
with two recent reports of RSV infection inducing IL-1β secretion in macrophages (131) 
and primary human airway epithelial cells (383) through an NLRP3- and caspase-1-
dependent mechanism. While LC3b-dependent autophagy directly regulates 
inflammasome activity in macrophages through selective degradation of ubiquitinated 
NLRP3 inflammasome platforms (249) and pro-IL-1β (320), further work will be 
required to establish this mechanism in epithelial cells during RSV infection.  The 
inability of LC3b
-/-
 cells to regulate inflammasome activation through autophagy may be 
further exacerbated by an inability to remove damaged mitochondria through mitophagy 
(235). Reactive oxygen species released by damaged mitochondria are required for 
NLRP3 inflammasome activation and caspase-1-mediated IL-1β production (234, 397), 
and this was recently verified in RSV-infected macrophages (131). Autophagy-deficient 
LC3b
-/-
 macrophages accumulated damaged mitochondria and mitochondrial ROS in 
response to LPS and ATP treatment, resulting in greater NLRP3 inflammasome 
activation and IL-1β secretion (235). As RSV infection was previously reported to 
increase numbers of morphologically altered mitochondria in human airway epithelial 
cells (398), an inability to sequester damaged mitochondria via LC3b-associated 
mechanisms likely contributes to increased inflammasome activation upon infection. 
Importantly, these data uncovered evidence of increased ER stress in LC3b
-/-
 
AECs upon RSV infection. Recent data indicated that RSV infection of A549 cells 
activates ER stress response signaling through IRE-1 and ATF6 (345). ER stress is 
known to upregulate pro-survival autophagy (332, 333), while numerous studies have 
shown a requirement for IRE-1 pathway signaling in the regulation of autophagy during 
the ER stress response (332, 399). It was also recently reported that the induction of ER 
stress activates the NLRP3 inflammasome and increases IL-1β secretion in a manner 
dependent on mitochondrial integrity (336). It is therefore plausible that ER stress in 
RSV-infected cells may serve the dual purpose of promoting cell survival through 
autophagy-mediated removal of viral nucleic acids and proteins, while simultaneously 
controlling NLRP3 inflammasome activation through degradation of damaged 
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mitochondria and assembled inflammasome platforms. Further studies will be required to 
elucidate the exact mechanisms underlying increased RSV-induced inflammasome 
activation and IL-1β secretion by LC3b-/- cells. 
These findings provide additional evidence for the role of autophagy during RSV 
infection in promoting the induction of antiviral Th1 responses to RSV in vivo. 
Furthermore, these results suggest that LC3b associated responses and autophagy serves 
as a critical negative regulator of inflammation during RSV infection, through limitation 
of IL-1β production by lung epithelial cells. The present studies highlight the unique, 
cell-specific contribution of autophagy proteins to inflammatory processes, and provide 
valuable insight into the induction and development of Th17-skewed responses during 
RSV infection. Ultimately, this information may inform novel treatments for severe RSV 
infection, and ultimately aid in vaccine design strategies. 
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Chapter 4 – Discussion and Future Directions 
 
4a. Autophagy in DC-mediated limitation of RSV-induced pathology in vivo 
The studies described in this dissertation provide novel evidence of a requirement 
for autophagy in the successful induction of antiviral responses to RSV. These findings 
agree with recent studies of immunological autophagy in the direct clearance of 
intracellular bacteria and viruses from infected cells, yet to our knowledge this represents 
the first demonstration of an in vivo requirement for immunological autophagy in the 
induction of protective responses to a respiratory virus.  
Our findings build on previous work that established the importance of autophagy 
in DCs in the production of pro-inflammatory cytokines and antigen presentation to T 
cells, and extend this knowledge to a translationally relevant animal model of RSV 
infection. Our studies documenting the development of pathological Th2 and Th17 
responses to RSV in mice deficient in different autophagy proteins is reminiscent of Th2-
biased and Th17-biased subsets of patients with severe RSV (107, 180, 375). The 
potential of dysregulated autophagic machinery to cause pulmonary disease has drawn 
considerable scientific interest in recent years, and autophagy gene variants are now 
associated with disease pathogenesis in COPD (400), cystic fibrosis (401), cigarette 
smoke-induced emphysema (386, 387, 402), and asthma (311, 403). The well-established 
correlation between severe RSV infection and subsequent development of chronic lung 
disease, combined with evidence of genetic predisposition precipitating these responses, 
may point to a common mechanism driving pathological responses to both RSV infection 
and environmental insults. While any relationship between impaired autophagy and 
neonatal illness susceptibility has yet to be investigated, there are several plausible ways 
in which subtle defects in the autophagic response could contribute to the development of 
severe RSV infections.  Insufficient neonatal immune responses  are partly due to the 
failure of infant DCs and macrophages to mature in response to antigen, as these cells 
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express lower levels of pattern recognition receptors and produce less cytokine in 
comparison to myeloid cells from adults (404). The reasons for this functional deficit are 
not fully understood, and it is plausible that an underlying failure to rapidly upregulate 
autophagy could underlie incomplete neonatal DC maturation. Our findings indicate that 
blockade of autophagy inhibits DC maturation and cytokine production in response to 
RSV, and attenuates production of the critical antiviral cytokine IL-12 (228, 230). 
Neonatal DCs are similarly deficient in IL-12 production (405) and in the induction of 
cytotoxic T cell responses to RSV (404). Any impaired autophagic upregulation could in 
turn be exacerbated by the Th2-biased adaptive immune system of infants, as the Th2 
cytokines IL-4 and IL-13 are reported to suppress autophagy in macrophages (255). 
While further studies would be required to prove a causal link between dysregulated 
autophagy and RSV-induced pathology in humans, these findings suggest that genetic or 
epigenetic disruption of autophagy may plausibly contribute to the development of 
pathogenic responses to RSV in human patients. 
We have also provided novel evidence of autophagy limiting inflammasome 
activity and IL-1β secretion by airway epithelial cells during RSV infection. It was 
recently demonstrated that RSV infection induces NLRP3 inflammasome activation in 
human airway epithelial cells and murine macrophages (131, 383), and our finding of 
increased IL-1β secretion by LC3b-/- DCs and epithelial cells correlates with the 
established role of autophagy in counteracting inflammasome activity in immune cells. 
IL-1β stimulates IL-17 production from CD4+ T cells (406), and elevated IL-1, IL-6 and 
IL-17 concentrations are observed both in lungs of RSV-infected LC3b
-/-
 mice and in the 
airway aspirates of infants hospitalized with RSV (374, 391, 392). Finally, our 
experiments provide evidence of the efficacy of IL-1Ra treatment in the amelioration of 
IL-17-dependent lung pathology. Recombinant human IL-1Ra has already been approved 
for patient use (anakinra, trade name Kineret), and further studies into the effectiveness 
of treating established RSV infection with IL-1Ra may provide evidence for a novel 
treatment option for severe RSV infections. Overall, these studies shed light on the 
importance of autophagy to the induction of antiviral immune responses and control of 
the inflammatory environment of the lung during RSV infection, and could potentially 
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inform the development of novel RSV vaccine formulations or the development of DC- 
or epithelium-targeted therapeutics.  
4b. Differential responses of Becn1
+/-
 and LC3b
-/-
 mice to RSV infection 
Several interesting discrepancies were uncovered between the responses of 
Becn1
+/-
 mice and LC3b
-/-
 mice to RSV infection (see Table 4-1). Both Becn1
+/-
 and 
LC3b
-/-
 mice were impaired in viral clearance and developed increased lung pathology in 
response to RSV. Nevertheless, Becn1
+/-
 responses were characterized by increased Th2 
cytokine expression and eosinophil infiltration into the lungs, while LC3b
-/-
 mice 
developed lung neutrophilia and an increased Th17-associated cytokine secretion profile. 
RSV-infected Becn1
+/-
 and 
LC3b
-/-
 DCs were both 
deficient in MHC-II surface 
expression, and both 
elicited aberrant CD4+ T 
cell responses, yet these 
responses were skewed 
toward Th2- and Th17- 
associated cytokines, 
respectively. These results 
reinforce the critical role of 
autophagy in DC function, 
and in DC initiation of 
antiviral CD4+ T cell 
response to RSV.  
However, the differential 
responses of Becn1
+/-
 and 
LC3b
-/-
 cells to RSV 
infection point to other 
 Becn-1+/- LC3b-/- 
Lungs   
Viral Clearance Delayed Delayed 
Mucus production Increased Increased 
Lung T cell cytokines IL-5, IL-13 IL-17a 
Granulocytes Eosinophils Neutrophils 
DCs   
MHC-II expression Decreased Decreased 
IL-12 production Decreased Decreased 
IL-1β , IL-6 production Decreased Elevated 
Elicited CD4+ T cell 
cytokines (co-culture) 
Th2 (IL-5, IL-13) Th17 (IL-17a) 
Epithelial cells   
IL-1β production No difference Elevated 
IL-6 production No difference Elevated 
Mitochondrial 
clearance 
Not investigated Impaired 
Table 4-1- Summary of responses of Becn1+/- and LC3b-/- mice to RSV 
infection. 
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intracellular processes intersecting with the autophagy machinery, and demonstrate how 
targeting different aspects of a conserved intracellular pathway can produce very 
different immunological results at the organismal level. 
One marked difference uncovered in these studies was the different cytokine 
responses of LC3b
-/-
 and Becn1
+/-
 epithelial cells upon RSV infection. LC3b
-/-
 epithelial 
cells produced more of the IRE-1-signalling-dependent cytokine IL-6 in response to 
RSV, while expression of IL-6 by RSV-infected Becn1
+/-
 epithelial cells was identical to 
wild-type controls ((228), see Figure 2-3 and Figure 3-5). The induction of ER stress 
signaling in RSV-infected Becn1
+/-
 epithelial cells was not investigated, yet these cells 
are likely to function normally with respect to the unfolded protein response (UPR). 
While Becn1 expression is required for ER stress-induced autophagy, ER stress signaling 
and the induction of the UPR proceed normally in the absence of Becn1 (407). Of note, 
the authors used silencing RNA to eliminate Becn1 production, rather than utilizing 
Becn1
+/-
 cells as in the current studies.  As the induction of the UPR triggers an 
upregulation of Becn1 gene expression (334, 407), it is plausible that cells with one 
functioning copy of the Becn1 gene may express sufficient Becn1 for some autophagic 
mitigation of ER stress to occur. In contrast, LC3b
-/- 
epithelial cells are unable to remove 
damaged ER through ER-phagy, as LC3b expression is required for this process (331). 
This inability to alleviate ER stress likely augments IL-1β production by RSV-infected 
LC3b
-/-
 cells, as prolonged ER stress activates the NLRP3 inflammasome by triggering 
mitochondrial ROS production (335, 336, 397). Finally, ER stress-driven inflammasome 
activation in LC3b
-/-
 cells is exacerbated by an inability to degrade mitochondria, as 
membrane-bound LC3b is a critical receptor for proteins targeting depolarized 
mitochondria to forming autophagosomes (331, 408). Thus, the ability to mitigate ER 
stress and sequester damaged mitochondria during RSV infection may ultimately explain 
the differential cytokine expression profiles of Becn1
+/-
 and LC3b
-/-
 epithelial cells.  
In contrast to epithelial cells, TLR-dependent DC maturation and innate cytokine 
production requires the rapid upregulation of autophagosome formation in response to 
RSV, with baseline autophagosome numbers increasing 4-fold in as little as 30 minutes 
post-infection (timing observation unpublished; see Figure 2-4). Although Becn1
+/-
 DCs 
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have one functional copy of the gene encoding Becn1, we found that this was not 
sufficient to allow the immediate upregulation in autophagosome formation observed in 
WT DCs in response to RSV. In keeping with our previous studies identifying a 
requirement for autophagy in TLR activation and MHC-II surface expression in RSV-
infected DCs (230), both Becn1
+/-
 and LC3b
-/-
 DCs were deficient in production of the 
key innate cytokine IL-12 and in surface upregulation of MHC-II. Consequently, 
autophagy-deficient Becn1
+/-
 and LC3b
-/-
 DCs were impaired in the ability to elicit 
antiviral CD4+ T cell responses. These findings reinforce the importance of rapid 
autophagosomal delivery of viral RNA and peptides to endosomal compartments, thereby 
facilitating TLR-dependent DC maturation, IL-12 production, and antigen presentation 
function. 
While both Becn1
+/-
 and LC3b
-/-
 DCs displayed altered innate cytokine production 
profiles in response to RSV, secretion of IL-1β and IL-6 by RSV-infected LC3b-/- DCs 
was significantly greater in comparison to WT controls. In contrast, Becn1
+/-
 DCs 
produced less IL-1β and IL-6 in response to RSV. It is possible that this discrepancy in 
IL-1β and IL-6 production is due to the ability of RSV-infected Becn1+/- DCs to manage 
ER stress, while LC3b
-/- 
DCs are unable to do so. The pharmacological induction of ER 
stress in macrophages augments IL-6 production in response to TLR agonists (409), 
which may explain elevated IL-6 secretion by LC3b
-/-
 DCs. The differential secretion of 
IL-1β by RSV-infected Becn1+/- and LC3b-/- DCs could also be due to an inability of 
LC3b
-/-
 DCs to clear depolarized mitochondria, as the targeting of damaged mitochondria 
to forming autophagosomes requires LC3b expression (408). Indeed, inhibition of 
autophagy in LPS- and ATP-treated LC3b
-/-
 macrophages promoted rapid cytosolic 
accumulation of depolarized mitochondria, leading to increased NLRP3 inflammasome 
activation and IL-1β secretion (235). While the authors reported a slight accumulation of 
depolarized mitochondria in Becn1
+/-
 macrophages, LC3b
-/-
 macrophages showed a far 
more pronounced increase in mitochondrial accumulation, cytosolic ROS production, and 
IL-1β secretion in response to LPS and ATP treatment  (235). This raises the possibility 
that Becn1
+/-
 macrophages may be able to remove some damaged mitochondria when 
stimulated with a less-potent inflammasome activator, and therefore do not produce 
excessive IL-1β as LC3b-/- macrophages do when infected with RSV.  Further studies 
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would be required to fully elucidate the potential relationship between ER stress 
signaling, mitochondrial clearance, and inflammasome activation in RSV-infected 
Becn1
+/-
 and LC3b
-/-
 DCs. 
Despite common findings of impaired viral clearance, increased mucus 
production, and granulocyte infiltration into lungs of RSV-infected Becn1
+/-
 and LC3b
-/-
 
mice, some key differences were found. Elevated Th2- and Th17-associated cytokine 
production observed in lungs of RSV-infected Becn1
+/-
 and LC3b
-/-
 mice correlated with 
the induction of Th2- and Th17-biased CD4+ T cell responses by Becn1
+/-
 and LC3b
-/-
 
DCs, respectively. The Th2-associated lung pathology observed in Becn1
+/-
 mice is 
primarily due to a deficiency in DC-mediated induction of antiviral CD4+ T cell 
responses, as RSV-pulsed Becn1
+/-
 DCs administered into the lungs of WT mice elicited 
increased Th2 cytokine responses and lung pathology upon subsequent RSV challenge. 
This was further upheld by cell culture experiments, where no differences in Becn1
+/-
 
epithelial cell cytokine production were detected in response to RSV.  
In contrast, examination of LC3b-deficient mice revealed increased IL-17-
dependent lung pathology in response to RSV, as neutralization of IL-17 ameliorated 
lung inflammation and restored IFNγ production and viral clearance. This finding 
concurred with previous studies in our laboratory, which found that IL-17 directly 
inhibits viral clearance through suppressing IFNγ production and cytotoxic activity by 
CD8α+ T cells (374). In agreement with findings in Becn1+/- mice, the skewed CD4+ T 
cell cytokine environment in the lungs of infected LC3b
-/-
 mice is due to altered DC-
mediated induction of antiviral CD4+ T cell responses. This is evidenced by increased 
elicitation of IL-17 production from CD4+ T cells by RSV-infected LC3b
-/-
 DC, and 
further supported by the development of elevated lung pathology in RSV-infected WT 
chimaeric mice reconstituted with LC3b
-/-
 bone marrow. However, we found a substantial 
contribution of airway epithelial cell cytokine production to the development of Th17-
associated pathology in RSV-infected LC3b
-/-
 mice, as reconstitution of LC3b
-/-
 mice 
with WT bone marrow produced augmented lung neutrophil recruitment and IL-17 
production. This ultimately suggests that, in the absence of functional autophagy, an 
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excessively inflammatory lung environment amplifies the skewed CD4+ T cell response 
initiated by autophagy-deficient DCs, leading to augmented lung pathology.  
4c. Future studies 
Much of our knowledge of the mechanisms of epithelial cell and DC responses to 
pathogenic insults are derived from studies utilizing transfected cell lines, purified PRR 
ligands, and pharmacological agents. While these studies are of considerable worth to 
elucidating the intracellular mechanics of immune cell responses to specific stimuli, they 
are not always easily translated to the context of live viral infection. Viruses are dynamic 
entities that have been evolutionarily selected to commandeer host cell processes for their 
own ends, particularly in order to replicate and inhibit host antiviral signaling. Any study 
of host defense against viral infection in cultured cells, or at the organismal level, must 
therefore take viral subversion into account. 
One interesting avenue to pursue would be untangling the interaction between 
RSV-encoded virulence proteins NS1/2 and SH (410), and host autophagy, ER stress, and 
inflammasome activation. Many viruses block or induce autophagy activation, yet it is 
currently unknown whether RSV modulates autophagy in this way. The RSV 
nonstructural proteins NS1 and NS2 colocalize with mitochondrial IPS-1 in infected cells 
(35, 365, 411), promote the degradation of IPS-1-binding RIG-I and its downstream 
signaling molecules IRF3 and Iκκε (411, 412), and delay host cell apoptosis (30). IPS-1 
localizes to the junction between mitochondria and ER mitochondria-associated 
membranes (ER-MAMs) (413), which is also the site of autophagosome generation 
(337). As NS1/2-mediated degradation of RIG-I is only partially dependent on 
proteasome activity (412), the remainder could be due to autophagosomal sequestration 
and degradation of bound mitochondria. RSV is known to form viral ‘inclusion bodies’ in 
the cytoplasm of host epithelial cells, which colocalize with mitochondrial markers (414). 
A recent study of a novel phlebovirus found that NS-dependent inclusion bodies function 
to sequester TBK1, Iκκε, and IRF3, thereby enabling viral suppression of IFNβ 
production (415). As RSV NS1 is reported to interact with Iκκε and promote its 
degradation through a proteasome-independent mechanism (365, 411), it seems plausible 
that autophagy could be involved in this process. Furthermore, the induction of 
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mitophagy by NS1/2 could expedite viral blockade of RIG-I/IPS-1-mediated IFNβ 
production through removing mitochondrial IPS-1 and RIG-I (35). The induction of 
mitophagy could also potentially explain NS1/2-dependent delayed intrinsic apoptosis 
(30) through the removal of mitochondria from the cytosol. Our own findings indicate 
that RSV-induced, mitochondria-containing inclusion bodies in epithelial cells are 
ATG5-positive (see Figure 3-6), warranting further investigation to answer these 
questions. 
The studies detailed in this dissertation demonstrate that inflammasome-mediated 
secretion of IL-1β is an important driver of Th17-dependent lung pathology in vivo, and 
that LC3b expression is critical to the control of IL-1β production. It is known that RSV 
induces NLRP3 inflammasome activation through a mechanism requiring potassium 
efflux and the generation of mitochondrial ROS (131, 383), but exactly how RSV induces 
this response remains to be elucidated. The RSV protein SH was recently identified as a 
viroporin targeting the Golgi, ER-MAMs, and mitochondria, and was required for RSV-
induced IL-1β production (383). This raises the possibility that this protein could directly 
induce ion transfer to or from mitochondria, or perhaps indirectly promote inflammasome 
activation through the induction of ER stress. Viroporins encoded by other viruses have 
been shown to activate ER stress by altering ER calcium ion gradients (342, 343), and 
calcium release from the ER is a potent inducer of both autophagy (416) and NLRP3 
inflammasome activation (417). The induction of NLRP3 inflammasome activation 
during ER stress is known to be dependent on ion channel expression (336), yet any 
contribution of the SH protein to ER stress remains to be addressed. 
Future studies could also examine the relative contributions of different ER stress 
signaling pathways, and their interaction with TLR signaling, in the production of pro-
inflammatory cytokines. The pioneering report of ER stress induction by RSV found 
evidence of IRE-1α-dependent control of viral replication in infected epithelial cells, but 
no evidence of PERK activation (345). Interestingly, pharmacological induction of 
signaling downstream of PERK attenuates IRE-1α-dependent IL-6 production by primary 
epithelial cells undergoing ER stress (418), suggesting that the induction of PERK may 
suppress signaling through other ER stress sensors. PERK signaling may also reduce 
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viral replication in RSV-infected epithelial cells (419). Additional experiments are 
needed to illuminate the signaling pathways downstream of IRE-1α and PERK that lead 
to reduced viral replication and/or IL-6 production in the context of RSV. 
Finally, the relative importance of ER stress signaling and autophagy is likely 
dependent on the cell type, and future studies addressing cell-specific responses may lead 
to better-designed and properly-targeted therapeutic development. Airway epithelial cells 
are primary replicative targets for respiratory viruses, providing considerable 
evolutionary incentive for the emergence of viral proteins that suppress epithelial 
antiviral signaling. In the never-ending conflict between host and pathogen, the detection 
of rapid viral protein synthesis through sensors of ER stress provides another critical 
danger signal to the cell. Several viruses, including RSV, are now known to modulate 
IRE-1α signaling in human bronchial epithelial cells in order to enhance viral replication 
(345, 420, 421).  In contrast, our previous data indicates that RSV replication is quickly 
attenuated within infected WT DCs (228), suggesting that these cells respond so rapidly 
that RSV may not have the opportunity to generate severe ER stress under normal 
circumstances. It may also be to the advantage of professional antigen-presenting cells to 
gather more nuanced, PRR-dependent information about encountered pathogens, rather 
than sending out general distress signals. The findings and additional questions raised by 
the current studies will ultimately contribute to the effort to design novel treatments for 
established RSV infections, and will hopefully aid in the eventual design of an effective 
vaccine. 
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